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Résumé 
La dystrophie cornéenne endothéliale de Fuchs (FECD, pour l’abréviation du terme 
anglais « Fuchs endothelial corneal dystrophy ») est une maladie de l'endothélium cornéen. 
Sa pathogenèse est mal connue. Aucun traitement médical n’est efficace. Le seul traitement 
existant est chirurgical et consiste dans le remplacement de l’endothélium pathologique par 
un endothélium sain provenant de cornées de la Banque des yeux.  Le traitement 
chirurgical, en revanche, comporte 10% de rejet immunologique. Des modèles 
expérimentaux sont donc nécessaires afin de mieux comprendre cette maladie ainsi que 
pour le développement de traitements alternatifs. Le but général de cette thèse est de 
développer un modèle expérimental de la FECD en utilisant le génie tissulaire. Ceci a été 
réalisé en trois étapes. 1) Tout d'abord, l'endothélium cornéen a été reconstruit par génie 
tissulaire en utilisant des cellules endothéliales en culture, provenant de patients atteints de 
FECD. Ce modèle a ensuite été caractérisé in vitro. Brièvement, les cellules endothéliales 
cornéennes FECD ont été isolées à partir de membranes de Descemet prélevées lors de 
greffes de cornée. Les cellules au deuxième ou troisième passages ont ensuite été 
ensemencées sur une cornée humaine préalablement décellularisée. Suivant 2 semaines de 
culture, les endothélia cornéens reconstruits FECD (n = 6) ont été évalués à l'aide 
d'histologie, de microscopie électronique à transmission et d’immunomarquages de 
différentes protéines. Les endothélia cornéens reconstruits FECD ont formé une 
monocouche de cellules polygonales bien adhérées à la membrane de Descemet. Les 
immunomarquages ont démontré la présence des protéines importantes pour la 
fonctionnalité de l’endothélium cornéen telles que Na+-K+/ATPase α1 et Na+/HCO3-, ainsi 
qu’une expression faible et uniforme de la protéine clusterine. 2) Deux techniques 
chirurgicales (DSAEK ; pour « Descemet stripping automated endothelial keratoplasty » et 
la kératoplastie pénétrante) ont été comparées pour la transplantation cornéenne dans le 
modèle animal félin. Les paramètres comparés incluaient les défis chirurgicaux et les 
résultats cliniques. La technique « DSAEK »  a été difficile à effectuer dans le modèle félin. 
Une formation rapide de fibrine a été observée dans tous les cas DSAEK (n = 5). 3) 
Finalement, la fonctionnalité in vivo des endothélia cornéens reconstruits FECD a été 
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évaluée (n = 7). Les évaluations in vivo comprenaient la transparence, la pachymétrie et la 
tomographie par cohérence optique. Les évaluations post-mortem incluaient la 
morphométrie des cellules endothéliales, la microscopie électronique à transmission et des 
immunomarquage de protéines liées à la fonctionnalité. Après la transplantation, la 
pachymétrie a progressivement diminué et la transparence a progressivement augmenté. 
Sept jours après la transplantation, 6 des 7 greffes étaient claires. La microscopie 
électronique à transmission a montré la présence de matériel fibrillaire sous-endothélial 
dans toutes les greffes d’endothelia reconstruits FECD. Les endothélia reconstruits 
exprimaient aussi des protéines Na+-K+/ATPase et Na+/HCO3-. En résumé, cette thèse 
démontre que les cellules endothéliales de la cornée à un stade avancé FECD peuvent être 
utilisées pour reconstruire un endothélium cornéen par génie tissulaire. La kératoplastie 
pénétrante a été démontrée comme étant la procédure la plus appropriée pour transplanter 
ces tissus reconstruits dans l’œil du modèle animal félin. La restauration de l'épaisseur 
cornéenne et de la transparence démontrent que les greffons reconstruits FECD sont 
fonctionnels in vivo. Ces nouveaux modèles FECD démontrent une réhabilitation des 
cellules FECD, permettant d’utiliser le génie tissulaire pour reconstruire des endothelia 
fonctionnels à partir de cellules dystrophiques. Les applications potentielles sont 
nombreuses, y compris des études physiopathologiques et pharmacologiques. 
Mots-clés: Dystrophie cornéenne endothéliale de Fuchs, transplantation de la 
cornée, génie tissulaire, cellules endothéliales cornéennes, culture cellulaire, modèle félin. 
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Abstract 
Fuchs endothelial corneal dystrophy (FECD) is a primary disease of the corneal 
endothelium. Its pathogenesis is poorly understood. No medical treatment is effective. 
Surgical treatment (the only available treatment) carries 10% of immunogenic rejection. 
Experimental models are needed in order to better understand the disease and to investigate 
potential autologous treatments (to prevent immunogenic rejection). The overall goal of this 
thesis is to develop an experimental model for FECD using tissue engineering. This was 
achieved in three steps. 1) An in vitro tissue-engineered FECD model was created and 
characterized. Briefly, Descemet’s membranes from patients with late-stage FECD 
undergoing Descemet’s Stripping Automated Endothelial Keratoplasty (DSAEK) were 
used to isolate and culture FECD endothelial cells. Second or third-passaged FECD 
endothelial cells were seeded on a previously decellularized human cornea. After 2 weeks 
in culture, TE-FECD corneas (n=6) were assessed using histology, transmission electron 
microscopy (TEM) and immunofluorescence labeling of various proteins. TE-FECD 
endothelium yielded a monolayer of polygonal cells well adhered to Descemet’s 
membrane. The TE-FECD corneal endothelium expressed the function-related proteins 
Na+-K+/ATPase α1 and Na+/HCO3-. Clusterin expression was faint and uniform.  2) In 
order to determine the best surgical procedure to transplant the TE-FECD corneas in the 
feline model, a DSAEK procedure was evaluated and compared to penetrating keratoplasty 
technique. DSAEK assessments included surgical challenges and clinical outcomes. 
DSAEK technique was challenging to perform in the feline model. Rapid fibrin formation 
was observed in all DSAEK cases (n=5). 3) The in vivo functionality of the TE-FECD 
corneas was assessed. TE-FECD corneas were grafted in the feline model (n=7) using 
penetrating keratoplasty procedure and observed for seven days. In vivo assessments 
included transparency, pachymetry, optical coherence tomography, endothelial cell 
morphometry, TEM and immunostaining of function-related proteins. After transplantation, 
pachymetry gradually decreased and transparency gradually increased. Seven days after 
transplantation, 6 out of 7 grafts were clear. Post-mortem TEM showed subendothelial 
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loose fibrillar material deposition in all TE-FECD grafts. The TE grafted endothelium 
expressed Na+-K+/ATPase and Na+/HCO3-. This thesis demonstrates that endothelial cells 
from late-stage FECD corneas can be used to engineer a corneal endothelium. Compared to 
DSEAK, penetrating keratoplasty is a more appropriate procedure for corneal 
transplantation in the feline model, since the DSAEK procedure in the feline model 
presently yields inconsistent clinical results. Restoration of corneal thickness and 
transparency demonstrates that the TE-FECD grafts are functional in vivo. This novel 
FECD living model suggests a potential role of tissue engineering for FECD cell 
rehabilitation. Potential applications are numerous, including pathophysiological and 
pharmacological studies. 
Keywords: Fuchs endothelial corneal dystrophy; corneal transplantation; tissue 
engineering; corneal endothelial cells; cell culture; feline model. 
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Introduction 
A century ago, the Viennese ophthalmologist Ernst Fuchs reported thirteen cases of 
bilateral central corneal clouding in elderly patients.1 Subsequent investigations found that 
Fuchs endothelial corneal dystrophy (FECD) is caused by a primary abnormality of the 
corneal endothelium. The course of FECD usually spans 10 to 20 years. It becomes 
clinically evident in the fourth to fifth decade of life. Progressive corneal edema eventually 
leads to profound and painful vision loss.2-6 The etiology of FECD is still poorly 
understood. Corneal edema is thought to result from decreased endothelial cell density, 
increased endothelial permeability and decreased endothelial pump function.7-12 There is 
mounting evidence that oxidative stress,13-15 DNA damage,16 protein unfolding response17 
and apoptosis18  may play a role in FECD pathogenesis. 
In 2010, FECD was responsible for 28% of the 42,642 corneal grafts performed in 
the United-States.19 There is no medical treatment for FECD. The current management is 
based on the surgical replacement of the diseased endothelium with a healthy endothelium 
from an eye bank cornea, either by penetrating keratoplasty (PKP) or, now more frequently, 
using a Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) procedure.20 
Allografts, however, carry up to 45% chances of at least one rejection episode (10% on 
average).21 The most common causes of secondary corneal graft failure are endothelial 
failure (29%) or immunologic endothelial rejection (27%).22  
Human corneal endothelial cells are arrested in the G1-phase of the cell cycle23 and 
do not proliferate in vivo. However, they can proliferate in vitro in response to growth-
promoting agents.24-26 Previous studies in the laboratory showed that normal feline corneal 
endothelial cells can be cultured and can retain function in vitro and in vivo.27-29 A previous 
study also demonstrated the first evidence of successful culture, without viral transduction, 
of corneal endothelial cells isolated from DSAEK specimens obtained from patients with 
FECD.30  
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Research Objectives 
My first objective was to evaluate the feasibility of tissue engineering a corneal 
endothelium using endothelial cells from patients with FECD. Outcome parameters 
included endothelial cell morphometery using alizarin red and trypan blue staining, tissue 
integrity using regular histology, immunofluorescence labelling of function-related protein 
expression and ultrastructure using transmission electron microscopy.  
My second objective was to determine the most appropriate surgical technique to 
transplant a corneal graft into the feline animal model. DSAEK procedure was evaluated. 
The ideal surgical technique should not cause trauma to the endothelial cells and should not 
induce an inflammatory reaction. Surgical challenges, clinical outcomes and postoperative 
complications were evaluated.  
 My last objective was to evaluate the functionality of a corneal endothelium tissue-
engineered (TE) using corneal endothelial cells from patients with FECD cultured on a 
devitalized stromal carrier and transplanted in the living feline model. Outcome parameters 
included clinical functionality using corneal transparency, pachymetery, optical coherence 
tomography, endothelial cell morphometery using alizarin red and trypan blue staining, 
tissue integrity using histology, immunofluorescence labelling of function-related proteins 
and ultrastructure using transmission electron microscopy. 
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1 Chapter I:          
 The Normal Human Cornea
4 
 
 
1.1 Anatomy of the Human Cornea 
The cornea is the anterior transparent connective tissue of the eye. It represents the 
primary structure barrier as well as the major refractive compound of the eye. Corneal 
transparency, which depends on the structural anatomy and physiology of the corneal 
components, is essential for light perception of the retina; any distortion of the transparency 
will result in a decrease of the quality (i.e. aberrations) and/or the quantity (i.e. acuity) of 
vision.31 
In emmetropic adults, the average white-to-white diameter of the cornea is 11.5 to 
12.3 mm.  The central corneal thickness ranges from 528 to 588 µm and gradually increases 
towards the periphery.32  
The cornea is classically composed of five distinguishable layers. Three of them are 
cellular (epithelium, stroma and endothelium) and two are acellular (Bowman’s and 
Descemet’s membranes) (Figure 1).  
 
Figure 1: The five layers of the cornea (from Wilmer Eye Institute at Johns Hopkins) 
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1.1.1 Epithelium 
The corneal epithelium forms the first barrier separating the eye from the 
environment. It is composed of a stratified non-keratinized squamous epithelium of 4 to 6 
cell layers (40 to 50 µm in thickness). These layers are divided from posterior to anterior 
into: basal, wing and superficial cells. Corneal epithelial lifespan ranges from 7 to 10 days 
and the cells go through systematic involution, apoptosis and desquamation. This 
progression leads to a complete renewal of the epithelium every week.33 The main source 
of corneal epithelial regeneration is the epithelial stem cells, which are located within the 
basal interpalisade epithelial papillae of the Palisades of Vogt at the limbus (extreme 
periphery of the cornea). Limbal stem cells are slow-cycling undifferentiated cells that are 
presupposed to undergo asymmetric division giving rise to corneal epithelial cells. Upon 
dividing, one daughter cell remains within the niche to replenish the stem cell population, 
while the other detaches from its basement membrane and becomes a transient amplifying 
cell (TAC) committed to differentiate. TAC cells then migrate towards the center of the 
cornea and start to differentiate into basal cells (Figure 2).34  
 
Figure 2: Limbal stem cell niche scheme.34 
   6 
 
The basal cell layer consists of a single row of columnar cells (~20 µm tall) which 
are capable of mitosis.35 They are the source of wing and superficial cells that are incapable 
of mitosis. Basal cells have lateral intercellular junctions (gap and adherent junctions) and 
possess hemidesmosomes to their basement membrane. They secrete their basement 
membrane (0.05 µm in thickness) that contains collagen type IV and laminin.31 
Wing and superficial cells form 4 to 6 rows of cells that possess tight lateral 
intercellular junctions. Superficial cells have extensive apical microvilli and microplicae, 
which are covered by the glycocalyceal and the mucinous layers of the tear film (Figure 
3).31 
The regular thickness, the moistened status and the smooth surface of the epithelium 
play a role in the refractive property of the cornea. The epithelium also plays a role in 
protecting the underlying corneal layers from physical and chemical injuries and prevents 
tears from penetrating into the stroma, which could cause edema.   
 
Figure 3: Corneal epithelial layers.31 
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1.1.2 Bowman’s Membrane 
Bowman’s membrane (10-15 µm in thickness) lies posterior to the basement 
membrane of the epithelium. It is not a true membrane as it is an acellular condensation of 
collagen fibers and proteoglycans of the anterior portion of the stroma. It does not exist in 
many mammals (i.e. cats). Its physiological role is unclear. In cases of injury, this 
membrane does not regenerate and forms a scar.31 
1.1.3 Stroma 
The corneal stroma provides the volume of the structural skeleton of the cornea and 
constitutes 85% to 90% of its thickness. The transparency of the stroma is unique among 
other collagenous structures and results from the precise arrangement of the stromal 
collagen fibers and its extracellular matrix (ECM), which is hydrophilic and can absorb 
amounts of water equal to 1000 times its volume (Figure 4).36, 37 The corneal endothelium 
plays a critical role in maintaining the relatively dehydrated state of the stroma, thus 
preserving the precise organisation of the stromal collagen fibers.  
 A collagen fiber is composed of parallel bundles of fibrils which bind laterally and 
end-to-end to form a fiber with a uniform diameter. Collagen fibers in the stroma are 
spaced at a regular distance and are packed in parallel to form a lamella. The stroma 
consists of 200 to 250 distinctive lamellae, each of which is arranged at an angle relative to 
the other and runs from limbus to limbus.37 The central stroma is thinner than the peripheral 
one, and the collagen fibers change their direction and run circumferentially when they 
arrive near the limbus.38 Posterior lamellae are more arranged and less rigid than the 
anterior ones. This biomechanical difference is translated clinically in a stromal edema that 
is more marked posteriorly, pushing on the Descemet’s membrane and thus causing 
Descemet folds. This difference is also observed surgically: posterior lamellar dissection of 
the cornea has less resistance force than the anterior one.31  
Stromal collagen fibers consist mainly of collagen type I in a triple-helix structure 
with significant amounts of type V collagen to achieve their uniform diameter. Collagen 
type VI and XII bind collagen fibers and contribute in maintaining the regularity of the 
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stromal structure. Keratan sulfate and chondroitin sulfate/dermatan sulfate, which are the 
ground substance of the stroma, play a role in regulating the hydration state and the uniform 
structure of the stroma.  
Keratocytes, which are the main cell type of the stroma, however, occupy only 2 to 
3% of its total volume. They are elongated cells that rest between collagen lamellae in a 
parallel manner (Figure 4). Keratocytes contain corneal crystallins that reduce cellular light 
scattering. They are also responsible of producing extracellular matrix (including 
glycosaminoglycans (GAG) and collagen molecules).39 
 
Figure 4: Transmission electron microscopy (TEM) of normal corneal stroma. (A) Stromal 
lamellae with embedded keratocyte. (B) Higher magnification view showing a keratocyte 
nuclei, rough endoplasmic reticulum, mitochondria and vacuoles. Note the precise 
organisation of the stromal collagen fibers.31  
1.1.4 Descemet’s Membrane 
Descemet’s membrane (DM) is the basement membrane of the corneal endothelium, 
situated between the stroma and the endothelium.  
The normal DM is composed of two regular layers (Figure 5):  
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• Anterior banded layer: It is present in the eye of the fetus of five months of 
gestation. Its thickness is approximately 3 µm and it remains the same at all ages. It 
has wide-spaced collagen bands of 110 nm. It contains long-range arrays of vertical 
bands that correspond to the large, regularly spaced domains of collagen VIII. 40 
• Posterior nonbanded layer: It is secreted by the endothelial cells after birth on the 
posterior surface of the banded fetal portion. Its thickness increases significantly 
with age, averaging ~2 µm at 10 years of age and ~10 µm at 80 years of age. Over 
the age of 70, it is considerably thicker in females. It appears homogeneous with a 
finely granular quality ultrastructurally; however, banded spindles can be observed 
(in 5 out of 24 normal corneas observed).41 
DM in normal adults is composed of collagen type IV (dominant), VIII and XII, 
laminin, perlecan, nidogen-1, nidogen-2, netrin-4, vitronectin and fibronectin.40, 42  
 
Figure 5: Transmission electron microscopy (TEM) of Descemet’s membrane (DM) 
showing posterior stroma (S), anterior (A) and posterior (P) layers of normal DM, and 
endothelium (EN).31 
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1.1.5 Endothelium 
Corneal specialists consider the endothelium as the soul of the cornea. In the mid 
19th century, Sir William Bowman first described the microscopic structure of the 
monolayer endothelium as a “delicate and perishable layer”.2 In 1920, Alfred Vogt first 
described the hexagonal morphology of the endothelial mosaic in vivo using slit lamp 
biomicroscope.43 
 At about the sixth week of gestation, corneal endothelial cells, originating from the 
neural crest (neuroectoderm), migrate centrally from the rim of the optic cup to form a 
monolayer of cubical cells.2 Over time, these cells flatten and start to secrete their basal 
membrane (DM). At birth, the endothelium is a uniform monolayer of about 10 µm in 
thickness and consists of ~350 000 cells (~3 000 cells/mm²) covering the entire posterior 
surface of the cornea and fusing with the cells of the trabecular meshwork at the periphery. 
DM also fuses peripherally with the trabecular beams where Schwalbe line defines the 
ending of DM and the beginning of the trabecular meshwork.31 
After birth, endothelial cells keep on flattening to stabilize at 4 to 6 µm thickness at 
adulthood. They appear as a uniform honeycomb-like mosaic with four to nine sides, about 
20µm in diameter and 250 µm² in cell area (Figure 6). Adjacent cells interdigitate, overlap 
and form gap and tight junctions at their lateral borders. The lateral membranes enclose a 
high density of Na+/ K+-ATPase pump sites. The individual endothelial cell contains a large 
oblong nucleus, numerous mitochondria (reflecting high energy demand for ion pumps), a 
rough endoplasmic reticulum (RER) and its ribosomes, and a prominent Golgi apparatus 
(indicating high protein synthesis including enzymes, structure proteins and extracellular 
matrix (ECM)) (Figure 5).2, 31    
Endothelial cells do not proliferate in vivo. Once a cell dies, the neighbouring cells 
will enlarge and migrate in order to maintain the integrity of the monolayer. Endothelial 
cell morphometry keeps on changing throughout life. From the second to ninth decades of 
life, the cell density decreases from  ~3300 cells/mm2 to ~2300 cells/mm2, the cell area 
increases from 290 to 450 µm², the coefficient of variation (CV) of mean cell area 
(polymegethism) increases from 0.22 to 0.29 and the percentage of hexagonal cells 
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decreases from 75% to 60% (pleomorphism), indicating that the individual endothelial cells 
become less uniform throughout life.44 The central endothelial cell density decreases at an 
average rate of 0.6% per year in normal corneas.45 There is no correlation between corneal 
thickness and endothelial cell density, cell area, coefficient of variation or cell shape. 
However, it has been noticed that eyes with endothelial cell density less than 500 cells/mm2 
may be at risk of developing corneal edema.31 
 
Figure 6: Specular microscopy photo of the normal corneal endothelium. Note the regular 
hexagonal pattern.31 
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1.2 Physiology of the Human Corneal Endothelium 
1.2.1 Corneal Deturgescence 
The corneal endothelium maintains corneal transparency by ensuring corneal 
deturgescence (a condition in which corneal stroma is relatively dehydrated (78% water 
content)), a process achieved through ionic pumps (Na+/K+-ATPase) and ion transporters 
such as the co-transporter Na+/HCO3-,2 while aquaporins (AQP) facilitate the flow of water 
in response to osmotic gradients created by those pumps.46   
The corneal stroma imbibes fluids due to presence of glycosaminoglycans (GAG) 
that create an osmotic pressure (the swelling pressure 60 mmHg) which pulls fluids from 
the aqueous humor into the stroma providing nutrition to the keratocytes (leaky barrier of 
the endothelium), while the corneal endothelium actively pumps the fluid out of the stroma 
(pump function and AQP of the endothelium). In normal conditions, the leaky barrier of the 
endothelium equals its pump function. If this equivalence breaks, fluids will diffuse 
excessively into the stroma, disrupting the uniform collagen fiber arrangement and resulting 
in light scattering and corneal opacity (Figure 7).  
 
Figure 7: Drawing 
illustrates the pump and 
the barrier function of 
the corneal endothelium. 
Modified from Waring 
et al.2 
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1.2.2 Barrier Function of the Endothelium 
The intercellular space between endothelial cells measures 25 to 40 nm. This space 
decreases to about 3 nm at the apical borders of the cells, where junctional complexes exist. 
These complexes consist of focal tight junctions (zonulae occludens) and gap junctions. 
They do not run continuously around the apical border of the cell; therefore, they do not 
form a watertight seal, allowing water and small particles to pass through the endothelium.2 
The integrity of these junctions depends on calcium. Thus, any compound causing 
calcium imbalance will affect barrier function (i.e. calcium-free solutions, plasmalyte -148). 
Any disruption of the barrier function will lead to an increase in the leak rate over the pump 
rate resulting in corneal edema.2    
1.2.3 Pump Function of the Endothelium 
Endothelial pumps consist of iceberg-like enzymes embedded in the lateral plasma 
membrane that actively transport ions from the stroma to the aqueous humor, creating an 
osmotic gradient that pulls out the water from the hydrophilic stroma.  Sodium/bicarbonate 
co-transporter actively transport sodium and bicarbonate ions into the aqueous humor, 
while sodium/potassium ATPase pumps actively exchange 3 sodium ions from inside the 
cell with 2 potassium ions from outside the cell. This pump is magnesium dependent and 
requires ATP to phosphorylate the enzyme. Many mitochondria populate the area near the 
cytoplasmic membrane to provide the ATP necessary to maintain the pump function.   
Although endothelial cell density declines throughout life, sodium/potassium 
ATPase pump site density remains constant regardless of the age, suggesting that the 
remaining endothelial cells adapt to cell loss by creating new pump sites in order to 
maintain normal pump site density and thus pump capacity.8 
The activity of endothelial pumps can be inhibited by a number of conditions 
causing corneal swelling, such as lowering of the temperature, ouabain, bicarbonate-free 
solutions and bromacetazolamide.2  
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1.2.4 Aquaporin Function of the Endothelium 
 Aquaporin (AQP) water channels are proteins that integrate in the cell’s membrane 
to facilitate the transmembrane solute-free water transport in response to osmotic gradients. 
AQP1 is expressed in the corneal endothelium. Its deficiency remarkably delays restoration 
of corneal transparency and thickness providing evidence that water extrusion from stroma 
through endothelium is mediated by AQP1. However, its mechanism remains unclear.46  
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2 Chapter II:        
 Fuchs Endothelial Corneal Dystrophy 
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In 1910, the Viennese ophthalmologist Ernst Fuchs (1851-1930) first described the 
entity presently recognized as Fuchs endothelial corneal dystrophy (FECD) when he 
reported 13 cases of bilateral slowly progressive central corneal clouding in elderly 
patients.1, 47 With the modest ophthalmologist’s examination tools at that time, Professor 
Fuchs concluded that the primary defect in these cases was in the corneal epithelium; he 
thus entitled his paper ‘Dystrophia Epithelialis Corneae’.  
However, since then, several studies have shown that pathological changes in FECD 
result from a primary disease of the corneal endothelium. All the accompanying changes 
have been shown to be secondary to the process involving the endothelium.2-6  
FECD is a common, progressive, bilateral, often asymmetric disease that leads to 
blindness. Its course usually spans 10 to 20 years. It becomes clinically evident at the age of 
forty to fifty; despite that, patients do not complain of visual symptoms for another 10 
years.2-6 
There is no efficient medical treatment for FECD. FECD accounts for 47.7% of the 
23,287 corneal endothelial transplantations performed in the United States in 2011,48 
making FECD the leading indication for corneal endothelial transplantations. Allografts, 
however, carry up to 45% chances of at least one rejection episode (10% on average).21 The 
most common causes of secondary corneal graft failure are endothelial failure (29%) and 
immunologic endothelial rejection (27%).22 
2.1 Clinical Stages 
Two major clinical staging systems for FECD have been described (Table 1). One 
of the most commonly used classification systems divides the course of FECD into four 
stages:3, 6, 49 
Stage I. The patient is asymptomatic. Clinical examination shows central droplet-like 
excrescences at the level of DM called guttae which are considered the hallmark of 
FECD.  Pigment dusting could also be seen at the level of the endothelium. DM appears 
gray and thick (Figure 8I).  
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Stage II. The patient starts suffering from blurred vision, glare and halos. Symptoms are 
worse in the morning and improve through the day. The patient may complain from 
foreign body sensation; however, he is free from pain. Clinical examination shows 
corneal guttae coalescing and spreading towards the peripheral of the cornea. Stromal 
edema starts posteriorly then progresses anteriorly reaching the epithelium and causing 
epithelial edema (Figure 8II).  
Stage III. The patient complains of low vision and episodes of pain. Clinical 
examination shows profound stromal edema and formation of sub-epithelial bullae that 
can cause nerve terminal compression or can rupture, causing pain. The cornea is at risk 
of infection at this stage (Figure 8III).  
Stage IV. The patient suffers from profound vision loss (visual acuity (VA) reaching 
hand movement (HM)). Pain is usually decreased. Clinical examination shows an 
opaque and vascularised cornea along with sub-epithelial fibrous tissue formation in 
response to chronic edema (Figure 8IV).   
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Figure 8: Clinical staging of FECD. (I) Stage I showing guttae and pigment dusting. (II) 
Stage II showing central corneal edema. (III) Stage III showing sub-epithelial bullae. (IV) 
Stage IV showing sub-epithelial fibrous tissue. 
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Reference  Stage I  Stage II  Stage III  Stage IV  
- Waring et al.2, 4  
- Wilson et al.5 
- Asymptomatic  
- Central guttae  
- Fine pigment dusting  
- DM: gray & thick 
- Blurred vision, glare & halos (worse in mornings)  
- Stromal & epithelial edema => sub-epithelial bullae  
- Episodes of pain  
- Patient more comfortable  
- VA drops  
- Sub-epithelial connective tissue  
- Peripheral corneal vascularization 
-  
- Adamis et al.3 
- Borboli et al.49 
- Elhalis et al.6 
- Asymptomatic  
- Central guttae  
- Pigment dusting  
- DM: gray & thick  
- Painless blurred vision (worse in mornings)  
- Stromal & epithelial edema  
- Epithelial & sub-epithelial bullae  
- Episodes of pain  
- VA drops to HM  
- Free of pain attacks  
- Subepithelial scar tissue  
Table 1: Clinical classification of Fuchs endothelial corneal dystrophy. 
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Laing et al.50 have described a classification of FECD based on endothelial cells and 
guttae appearance using specular microscopy. They have divided the severity of disease 
into five stages (Figure 9):  
Stage I. Corneal guttae are smaller than endothelial cells. 
Stage II. Corneal guttae are larger than endothelial cells. 
Stage III. Corneal guttae are larger than endothelial cells and adjacent endothelial 
cells appear abnormal. 
Stage IV. Corneal guttae coalesce and adjacent endothelial cells are difficult to 
identify. 
Stage V. Corneal guttae coalesce and adjacent endothelial cells are completely 
disorganized. 
 
Figure 9: Specular microscopy photos and drawing illustrate Laing morphological staging 
of FECD.50  
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Recently, the FECD Genetics Multi-Center Study Group proposed a novel 
classification method depending on the shape and distribution of guttae clinically. They 
grade FECD from 0 to 6 on a semiquantitative scale: 
Stage 0: no guttae. 
Stage 1: 1 to 12 central/paracentral nonconfluent guttae. 
Stage 2: more than 12 central/paracentral nonconfluent guttae.  
Stage 3: 1 to 2 mm of confluent central/paracentral guttae. 
Stage 4: more than 2 to 5 mm of confluent central/paracentral guttae. 
Stage 5: more than 5 mm of confluent central/paracentral guttae. 
Stage 6: more than 5 mm of confluent central/paracentral guttae with stromal and/or 
epithelial edema. 
Using this classification they demonstrated a gradual increase in central corneal 
thickness as FECD clinically progresses.51  
2.2 Associated Conditions 
Several studies have shown an association between FECD and keratoconus,52 age-
related macular degeneration,53 cardiovascular disease,54 axial hypermetropia55 and 
essential blepharospasm.56 The association between FECD and open-angle glaucoma is 
controversial. Buxton et al. demonstrated a decrease in aqueous humor outflow in FECD 
patient’s eyes compared to normal controls,57 while Roberts et al. showed no impairment of 
the outflow facility.58 Recently, Nagarsheth et al. demonstrated a higher prevalence of 
glaucoma and/or ocular hypertension in severe FECD patients compared to control subjects 
or unaffected family members.59 
2.3 Differential Diagnosis 
Corneal edema can be found in posterior polymorphous dystrophy (PPMD), 
congenital hereditary endothelial dystrophy (CHED), aphakic or pseudophakic bullous 
keratopathy and endothelial dysfunction due to anterior uveitis and herpes simplex 
keratitis.2-4, 49  
Corneal guttae are characteristic findings in the DM of FECD; however, they can be 
secondary to toxins, interstitial keratitis and trauma.2, 60, 61 They have been found neither in 
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PPMD nor in CHED.62-65  Hassall-Henle bodies have an aspect similar to guttae, but they 
are found only in the corneal periphery. They are considered normal findings in elderly 
subjects and never cause corneal edema.3, 6, 66  
2.4 Endothelial Morphology 
Specular microscopy in FECD shows presence of central corneal guttae, reduced 
endothelial cell count, variability in cell size (polymegethism) and variability in cell 
polygonal shape (pleomorphism) (also see section  1.1.5)(Figure 10).67  
 
Figure 10: Specular microscopy photo in FECD showing corneal guttae, polymegethism 
and pleomorphism.67 
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2.5 Histopathology 
2.5.1 Epithelium 
Transmission electron microscopy shows intracellular and intercellular edema. 
Surface cells retain tight junctions and intercellular desmosomes. Basal cells may detach 
from basement membrane due to accumulation of sub-epithelial fluid (Figure 11).68  
 
Figure 11: Epithelium in FECD. TEM is showing intercellular edema (*) and basal cell 
layer detachment due to sub-epithelial fluids (arrow).68 Scale bar: 5 µm.  
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2.5.2 Bowman’s Membrane 
Bowman’s membrane is usually intact or local breaks filled with connective tissue 
can be seen.68, 69 
2.5.3 Stroma 
Changes are seen in advanced stages of the disease including wavy collagen 
lamellae, wide interfibrillar spaces, degenerated keratocytes and granular or filamentous 
material inside or around the keratocytes. Lipid keratopathy is present in 72% of FECD 
(Figure 12).69  
 
Figure 12: Stroma in FECD. TEM showing degenerated keratocytes with variable 
dissolution cytoplasm and loss of organelles.69 Magnification: A: 20 000X, B: 30 000X  
2.5.4 Descemet’s Membrane 
Kayes and Holmberg70 studied the ultrastructure (TEM) of four corneal buttons with 
FECD and they noticed a large increase in DM thickness reaching 18 µm. They divided 
DM into 4 zones:  
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• Banded zone: close to the stroma, 100 nm banding. 
• Nonbanded zone.  
• Very regular banded zone with a periodicity of 90-125 nm that projects into the 
endothelium forming small hills to mushroom warts. They divided banding into: 
B1: usual DM fibers, B2: hexagon form, B3: fusiform spindle periodicity of 100 
nm, B4: periodicity of 64 nm, F1: fibers one-half B2 size and F2 smaller fibers.  
• Nonbanded zone. 
In another morphological study by Iwamoto et al.66 describing the TEM observation 
of 7 corneal buttons with FECD, DM was markedly thickened (2 to 4 times the normal) in 
6 cases. He divided DM into five regions: 
• Anterior banded region: with 100 nm banded pattern.  
• Nonbanded region: without clear banding. 
• Posterior banded region:  It was filled with 100 nm banded materials ("warts" are 
formed by its partial backward protrusions). 
• Border region: It was composed of groups of thin fibrils, long-spacing bundles of 
100 nm periodicity with two types of banded pattern and basement membrane-like 
material (Figure 13A-D). 
• Fibrillar region: It consisted of basement membrane-like material and collagen 
fibrils. Narrow fissures filled with cell debris and fibrils had been noticed (Figure 
13E-F). 
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Figure 13: Border region of DM in FECD. (A-D) Striated bodies: Wide-spacing bundles. 
(E-F) Narrow fissure (f) filled with cell debris (d) between the warts (w).66 Magnification; 
E-F: 38 000X 
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Bourne et al.71 studied the ultrastructure (TEM) of DM in 11 corneal buttons with 
FECD (all were phakic eyes). He found that DM was composed of up to four layers: 
• Anterior banded layer (fetal): It was normal in all cases showing 110 nm banding. 
Its thickness was 3.1 µm in average (excluding 3 cases where it was thickened). 
• Posterior nonbanded layer: It was present in 2/3 of the cases and absent in 1/3, with 
thickness of 2.8 µm in average when present. It was composed of a framework of 
tiny fibrils running randomly throughout. It appeared homogeneous in general. 
• Posterior banded layer: It was present in all cases, with thickness varying between 
10.7 and 23.2 µm (mean 16.6). It contained 110 nm banding, banded spindle-shaped 
bundles, 10 to 20 nm diameter fibrils and amorphous substance. Guttae were found 
in this layer when present. 
• Fibrillar layer: It was present in 7 corneas between the EC and the posterior banded 
layer. It contained 20 nm diameter fibrils randomly arranged and amorphous 
material. There was a statistical positive correlation between the preoperative 
corneal thickness and the thickness of this layer (Figure 14). 
 
Figure 14: Fibrillar layer (F) in FECD. Fibrils (20 nm in diameter) are loosely arranged 
among variable amounts of amorphous material. (E) indicates endothelium.71 
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Rodrigues et al.72 studied six corneal buttons with FECD. In light microscopy, they 
found that DM was thickened up to 3 times compared to normal with multiple guttata. 
Corneas from two patients showed oxylatan fibrils. TEM showed: 
• Normal anterior: 110 nm banding (3 µm thick) 
• Posterior granular portion: thinned 
• Posterior collagenous layer: (16 to 38 µm thick) showed abnormal 110 nm banding, 
spindle-shaped 10 to 15 nm fibrils and homogenous material, with variation of the 
configuration of the guttata. These banded areas corresponded to the same zones 
stained for oxylatan fibrils. 
Bergmanson et al.68 studied the ultrastructure of one pair of corneal button with 
FECD and he divided the layers of DM differently: 
• Posterior limiting lamina (PLL): This includes the fetal and postnatal layers, with a 
generalized thickening. 
• Posterior collagenous layer (PCL): It was sandwiched between the EC and the PLL. 
It had a more granular composition than PLL. Pigment granules were occasionally 
observed. Guttae contained inclusion bodies of various structures; most prominent 
were banded or cross-striated 133 nm bodies or fibrils, while other bodies were 
amorphous and non-striated. 
Yuen et al.69 studied the morphology of 32 corneal buttons of patients with FECD. 
They found that the average thickness of DM was 17.6 µm. They also showed that the 
ultrastructure of Decemet’s membrane was composed of up to four layers (Figure 15): 
• Anterior banded layer (fetal): It was present and relatively uniform in all cases of 
FECD. Its thickness was 3.2 µm in average. It had wide-spaced collagen with a 
periodicity of 110-120 nm.  
• Posterior nonbanded layer: It was present in 2/3 of the cases and absent in 1/3, with 
thickness of 3.2 µm in average when present. It appeared homogeneous. 
• Posterior banded layer: It was present in all cases, with thickness varying from 5.8 
to 32.1 µm (mean 15.9). It had wide-spaced collagen with a periodicity of 110-120 
nm. In ¼ of the cases a periodicity of 60 nm was observed. The characteristic guttae 
of FECD were contiguous with this layer in all the cases. Their mean maximal 
width and height were 15.1 µm, 4.6 µm respectively. 
• Fibrillar layer: It was present in 59% and absent in 41% of the cases, with average 
thickness of 7.8 µm when present. It was composed of a loose matrix of collagen 
with fibril diameters of 20-40 nm. In 1/3 of the cases, guttae were buried in this 
layer. In 7 cases, multiple waves of basal lamina were present along with foci of 
wide-spaced collagen with a periodicity of around 60 nm situated between this layer 
and the posterior banded layer.  
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Figure 15: Descemet’s membrane in FECD. 1: Anterior banded layer, 2: Posterior 
nonbanded layer, 3: Posterior banded layer, 4: Fibrillar layer. Guttae (asterisk) covered by 
attenuated endothelium (arrow).69 Magnification: 4200X. 
Zaniolo et al.30 confirmed the ultrastructure (TEM) of DM of patients with FECD. 
DM was thick (up to 40.8 µm in thickness) and composed of normal anterior banded and 
posterior nonbanded layer as well as abnormal posterior banded and a fibrillar layer which 
was observed in 6 cases. Guttae were present in ten cases, varied in number, size and shape. 
Striated bodies of 0.11 µm spacing were present in 12 of 13 cases. Some half sized striated 
bodies were observed in 2 cases. Their location, thickness and length varied between cases 
(Figure 16). 
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Figure 16: Ultrastructure of DM. (A) Normal DM with its two layers, an anterior banded 
layer (ABL) and a posterior non-banded layer (PNBL). (B-F) DM in FECD, (B) showing 
the presence of the abnormal posterior banded layer (PBL) and a fibrillar layer (FL), (C) 
showing large excrescences (guttae) in the posterior banded layer, (D) showing large 
striated bodies of 0.11 µm periodicity present on the edge of the posterior banded layer and 
perpendicular to the surface, (E) showing many large striated bodies with different 
orientations within guttae, (F) showing long striated bodies of 0.05 µm periodicity. Scale 
bars: (A-C) 5 µm, (D-F) 0.5 µm.30 
Gottsch et al.40 studied the ultrastructure of DM in a rare type of early-onset FECD 
with a L450W mutant of the COL8A2 gene and he compared it to a normal and common 
late-onset FECD (Figure 17):  
- DM in late-onset FECD was composed of: 
• Anterior banded layer. 
• Posterior nonbanded layer: had a fine-grained structure that lacked this regular 
periodicity.  
• Posterior banded layer: that had fine-grained layer containing short strips with 
transverse bands of about 120 nm periodicity. These strips presumably correspond 
to thin sections of irregular fibrous strands of structured collagen VIII.  
• Fibrillar layer: thin. 
- DM from the L450W COL8A2 mutant was 35 µm thick and  was composed of: 
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• Amorphous layer:  thin (1 µm) 
• Anterior banded layer: thick (10 µm)  
• Posterior nonbanded layer: normal 
• Internal collagenous layer (ICL): 2 µm thick, characterized by wide-spaced collagen 
strips with 120-nm spacing, and fibrous material that corresponded to a narrow layer 
that stained strongly with antibodies to collagen VIII.  
• Posterior striated layer: 12 µm thick, contained darker, horizontally striated 
material, and small, very electron-dense foci. 
 
Figure 17: Ultrastructure of DM. (A) normal control, (B) late-onset FECD, and (C) early-
onset FECD COL8A2 L450W mutant. Arrows and letters, to the right of (C) indicate layers 
of origin for the higher-magnification images (D–G). (D) ABL. (E) PNBL. (F) ICL. (G) 
PSL. Bar: (A–C) 2 µm; (D–G) 500 nm.40 
Immunohistochemistry showed that DM in early onset FECD stained positively for 
collagen VIII-α1 and α2 subtype in thin and thick branchlike fibers pattern respectively.  
Late onset FECD showed a positive staining of collagen VIII- α1 for the guttae, while α2 
had a thick branchlike staining pattern (Figure 18).  In early onset FECD, posterior DM had 
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a band of continuous staining for collagen VIII- α1 and IV, laminin and fibronectin. In late 
onset FECD, positive staining for collagen IV, laminin and fibronectin was observed near 
the posterior surface of DM and within the guttae (Figure 19).40  
 
Figure 18: Collagen VIII α1 and α2 in normal and FECD corneas. (A, B) Normal cornea, 
showing corneal endothelial cells and DM stained with both antibodies. AFL: anterior fetal 
layer. (C, D) Early-onset FECD COL8A2 L450W mutant cornea. Arrows: α1 and α2 thin 
and thick branchlike fibers in DM, respectively. (E, F) Late-onset FECD cornea. (E) Short 
arrows: guttae. Long arrows: α1-labeled brushlike fibrillar structures. (F) Long arrows: α2-
labeled brushlike thick fibers. Short arrows: guttae negative for α2.40 Scale bar 20 µm. 
 
Figure 19: Collagen IV, laminin, and fibronectin. In the normal cornea (A–C), collagen IV 
and fibronectin with a weak linear pattern in the anterior DM (arrows). In early-onset 
FECD (D–F), thick bands in the posterior portion of DM. In the late-onset form (G–I), 
intense labeling in the posterior layer of the DM and guttae (arrows).40 Scale bar: 20 µm. 
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However, Kenney et al.73 studied the composition of DM in normal and FECD 
corneas by biochemical and immunofluorescence methods. They found that both had the 
same amino acid compounds and collagen types with slight discrepancy of collagen chains. 
Levy et al.74 used immunoelectron microscopy to study the DM of FECD. They 
found that intranodal regions of widespaced collagen stained positively for collagen VIII 
and negatively for collagen types I, III, V and VI, fibronectin, laminin, P component and 
tenascin.  
Jurkunas et al.75 studied clusterin (that has cytoprotective and antiapoptotic 
properties) and transforming growth factor-β-induced protein (TGFβIp) (extracellular 
matrix protein that mediates cell adhesion by interacting with collagen, fibronectin, and 
integrins) expressions. Immunocytochemistry studies of FECD showed that they were co-
localized and increased in FECD DM compared to normal controls, with an increased 
intensity at the centers of guttae (Figure 20).  
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Figure 20: Clusterin and transforming growth factor-β-induced protein (TGFβIp) in DM of 
FECD.75 Note their colocalization in the centers of guttae.  
In conclusion, the most common way of describing DM in FECD is taken from 
Bourne’s article.71 DM in FECD is thicker than normal. It contains abnormal posterior 
collagenous layers (banded and fibrillar) that account for the increase of its thickness. 
However, variation in the composition does exist among the previous studies and even 
within each study that had a sufficient number of cases. Variation includes total thickness 
of DM; the thickness of each compounded layer; size, number, aspect and distribution of 
guttae and striated bodies (Table 2); presence and appearance of fibrillar layer. These 
variations in the composition could be explained by different genetic mutations responsible 
for this disease 40, 76 or by a different progression of the disease which may be caused by 
multi-factors causing stress to the endothelial cells (surgical trauma, prolonged corneal 
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edema). Knowing that all previous studies had obtained corneal buttons from patients who 
underwent corneal transplantation, we can conclude that DM was described in the end-
stage of the disease. It would thus be interesting to perform a study to document the 
evolution of DM structure throughout the disease progression (in vivo); ultra high 
resolution optical coherence tomography (UHR-OCT) seems to be a promising tool to 
perform such study.77 
Author, year Description Location 
Yuen,69 2005 Wide-spaced collagen with a periodicity of 110-120 nm. In 
¼ of the cases a periodicity of 60 nm was observed.  
Posterior banded layer 
Bourne,71 1982 110 nm banding, banded spindle-shaped bundles, 10 to 20 
nm diameter fibrils and amorphous substance  
Posterior banded layer 
Bergmanson,68 
1999 
Guttae contained inclusion bodies of various structures; 
most prominent were banded or cross-straited 133 nm 
bodies or fibrils, while other bodies were amorphous and 
non-straited. 
Posterior collagenous 
layer 
Iwamoto,66 1971 Long-spacing bundles of 1000 A periodicity with two types 
of banded pattern and basement membrane-like material. 
Posterior banded region  
& Border region 
Kayes,70 1964 They divided banding into:  
B1: usual DM fibers 
B2: hexagon form 
B3: fusiform spindle periodicity of 100 nm 
B4: periodicity of 64 nm 
F1: fibers one-half B2 size 
F2: smaller fibers.  
Banded zone 
Zaniolo,30 2012 
 
Striated bodies of 0.11 µm spacing were present in 12 of 13 
cases. Some half sized striated bodies were observed in 2 
cases. Their location, thickness and length varied between 
cases 
Posterior banded 
Gottsch,40 2005 Short strips with transverse bands of about 120 nm 
periodicity. These strips presumably correspond to thin 
sections of irregular fibrous strands of structured collagen 
VIII 
Posterior banded layer 
Table 2: Literature review of striated bodies in DM of FECD.  
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Corneal guttae are characteristic findings in DM of FECD. They have been found 
neither in PPMD nor in CHED. Abnormal posterior banded and fibrillar layers were mutual 
findings between FECD and both PPMD and CHED, but they were sometimes different in 
aspect, collagen type distribution and order in DM. Thus, these structural abnormalities are 
not pathognomonic of FECD. Hassall-Henle bodies also have an aspect similar to that of 
guttae, but a different location. 66 Similar findings were also observed in aphakic bullous 
keratopathy 78 and late endothelial failure.79    
2.5.5 Endothelium  
Kayes and Holmberg70 studied the ultrastructure (TEM) of 4 corneas from patients 
with FECD. They found that the endothelium was thin, distorted in shape and full of 
vacuoles (Figure 21). 
 
Figure 21: TEM of the endothelium in FECD showing Descemet’s membrane (D), wart 
(W), endothelium (E), anterior chamber (Ac), nuclei (N) and large vacuoles (arrows).  
Magnification: 2600X.70 
Iwamoto and DeVoe66  studied the ultrastructure (TEM) of 7 corneas from patients 
with FECD. The endothelium was thin, consisting of normal appearing cells (Figure 22) 
and two types of abnormal cells:  
• The Type 1 cell had cytoplasmic filaments, increased rough-surfaced endoplasmic 
reticulum (RER) and cytoplasmic processes, simulating fibroblasts (Figure 23).  
• The Type 2 cell had elongated RER and lysosomes within a less dense cytoplasm, 
and was probably a degenerate form of the Type 1 cell (Figure 24).  
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Loosening of firmed attachment between the endothelial cells was a common 
feature. Partial discontinuity of the endothelial coverage was also seen. 
 
Figure 22: Ultrastructure of FECD endothelium.TEM image showing normal appearing 
endothelial cell (e) over fibrillar layer (f). Large wart (W) is seen surrounded by arrows and 
posterior banded layer (P). Magnification: X 5,600.66 
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Figure 23: Ultrastructure of FECD endothelium. TEM image showing abnormal endothelial 
cells (Type I cell) viable-appearing fibroblast-like (A-C) characterized by (A) presence of 
pigment granules (p), degenerating endothelial cell (e2) leaving space (s), (B) cytoplasmic 
filaments (f), cytoplasmic process (p), (C) and abundant RER (er). Magnification: A: 
23,000X, B-C: 22,000X.66 
A 
C 
B 
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Figure 24: Ultrastructure of FECD endothelium. TEM image showing abnormal endothelial 
cells (Type II cell) degenerate form of type I cell (A-B) characterized by (A) elongated 
RER (er) lysosomes, (l) within a less dense cytoplasm, (B) degenerative endothelial cell (e) 
exposing to the anterior chamber, (C) vacuole (v). Magnification: A: 22,000X, B: 40,700X, 
C: l8,400X.66 
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Their hypothesis was that the endothelial cells in FECD become similar to 
fibroblasts and they start producing collagen fibrils and basement membrane-like material, 
forming abnormal layers of DM.  
Bergmanson et al.68 found that endothelial cell coverage was maintained while 
guttae progressed. Average endothelial cell thickness was 3.5 µm across the nucleus 
decreasing to 0.176 µm near the junction between cells and over the guttae. At these points 
the cells contained little or no cytoplasm between the apical and basal cell membranes, thus 
over considerable distances there were no organelles present. RER and mitochondriae were 
aggregated in the nuclear region.  
 
Figure 25: Ultrastructure of FECD endothelium. TEM image showing extremely thin 
endothelial cell over the guttae with intracellular pigment granules (arrow).68  
The nuclei were spaced farther apart than 20 μm suggesting a reduced cell count. 
They were located in the valleys between the guttae, while over the guttae the cells were 
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extremely thin. Some nuclei had very little heterochromatin (thus pale), with a nearly 
spherical shape, and the surrounding cytoplasm had a degenerative and swollen appearance. 
Electron dense granules measuring 0.6 μm in diameter were observed within endothelial 
cells and occasionally in the guttae or the posterior collagenous layer (Figure 25). The 
endothelial cells’ junctions appeared to be normal regardless of cell thickness, which led 
the authors to the conclusion that the endothelium still provided its normal barrier function 
while its fluid pump ability appeared compromised.  
Yuen et al.69 studied 32 cases of FECD using TEM. They found that endothelial 
cells were attenuated to atrophic (Figure 26). Large, round, melanin pigment granules were 
found in the endothelium of 7 cases. 
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Figure 26: Ultrastructure of FECD endothelium. TEM image showing degenerative 
endothelial cells (asterisks) covered by intact endothelium (arrows). Magnification: A: 
8,100; B: 15,000.69 
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2.6 Pathophysiology 
2.6.1 Endothelial Permeability 
In an in vivo study using slit lamp fluorophotometer, Burns et al.7 found an increase 
in endothelial permeability at early FECD stages compared with age/sex matched normal 
controls. These results suggest that the endothelial barrier dysfunction is the earliest defect 
in FECD.  
Few years later, Wilson et al.,9 from the same research group, using two-
dimensional scanning fluorophotometer, found no difference in endothelial permeability 
between patients with FECD and age/sex matched normal controls which suggests that the 
barrier function of the endothelium in early FECD stages is intact. The difference in 
conclusions between the two studies could be explained by a type I error in Burns’ study 
and a difference in measurements methods, which were more precise in Wilson’s study. 
2.6.2 Endothelial Pump Function 
Geroski et al.8 showed a significant increase in pump site density in moderate 
guttata compared to normal controls suggesting an increase in endothelial permeability at 
early FECD stages that can cause a compensatory increase in endothelial pump site density, 
thus pump function. After this sharp initial increase, however, there is a gradual decline in 
pump site density correlating with severity of the disease.10-12 
2.6.3 Aquaporin Expression 
Kenney et al.80 demonstrated a decrease in AQP1 expression in FECD endothelium 
compared to normal, suggesting that aquaporins may have an important role in the corneal 
fluid dynamics in the disease. 
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2.6.4 Corneal Sensitivity 
Ahuja et al.81 demonstrated a significant decrease in corneal sensitivity in FECD 
patients compared to normal subjects. Loss of sub-basal nerves and abnormal nerve 
morphology were suggested.  
2.6.5 Aqueous Humor and Serum Composition 
  In FECD patients, there is an increased concentration of fibrinogen degradation 
products in both serum and aqueous humor;82, 83 increased threonine, glutamine, and 
arginine; decreased asparagine, phosphoserine, and phosphoethanolamine concentration in 
the aqueous.84 Significance of these findings is unclear. No difference has been found in 
flbrinogen-derived metabolites, ascorbate, glucose, carbon dioxide, bicarbonate and pH 
levels in the aqueous.85 
2.6.6 Distribution of Chemical Elements 
Alterations in Descemet’s membrane were found in both guttae and non-guttae 
areas. Sulfur content is reduced by 40–50% and calcium content is increased with disease 
progression. Significance of these findings is unclear.86 
2.6.7 Inflammation Role 
Inflammation or any infectious, mechanical or toxic injury to the endothelium may 
play a role as a trigger in an eye genetically predisposed to develop FECD.2, 3 
2.6.8 Apoptosis and Oxidative Stress 
Apoptosis is programmed cell death. Using nucleus labelling and TUNEL (Terminal 
deoxynucleotidyl transferase dUTP nick end labeling) assays, the percentage of apoptotic 
epithelial cells, keratocytes and endothelial cell is significantly higher in FECD than normal 
controls.18, 87 DNA fragmentation is also seen in the epithelium, stroma and endothelium of 
FECD corneas.88 
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2.6.8.1 Protein Unfolding 
Protein folding is critical for cell function. Marked enlargement of RER is found in 
FECD endothelial cells, which is considered a sign of stress and unfolded protein response. 
Significant increase in levels of markers of unfolded protein response (GRP78, eIF2a and 
CHOP) is also found in FECD endothelial cells. Failure to alleviate RER stress by unfolded 
protein response can lead to cellular apoptosis.17 
2.6.8.2 Clusterin Expression 
Oxidative stress and reactive oxygen species can generate the overexpression of the 
clusterin (CLU) protein. CLU can help the cells to resist reactive oxygen species-mediated 
cellular injury.89 CLU gene expression results in the synthesis of different forms of CLU, 
located in different sub-cellular compartments. Secretory CLU (sCLU) helps binding to 
hydrophobic molecules, clearing cellular debris and scavenging denatured extracellular 
proteins. Nuclear CLU (nCLU) binds Ku-proteins, which are involved in DNA repair, 
promoting apoptosis in stressed cells. FECD endothelial cells overexpress both sCLU and 
nCLU compared to normal (Figure 27).14 
 
Figure 27: Clusterin expression in FECD. Endothelial cell nuclei clustered densely around 
the guttae with enhanced Clusterin staining at the cell membrane borders next to guttae and 
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inside guttae (arrow). Such a staining pattern suggests Clusterin’s role in eliciting 
endothelial cell clustering under stress.14 Clusterin: green, Nuclei: orange. 
2.6.8.3 Transforming Growth Factor β–Induced Protein (TGFβIp) 
TGFβIp is an extracellular matrix protein that mediates cell adhesion by interacting 
with collagen, fibronectin and integrins. There is an increase in production and 
modification of TGFβIp with aging in normal subjects. This increase, however, is greater in 
FECD. TGFβIp and CLU also co-localize in the centers of guttae.75 
2.6.8.4 Peroxiredoxins Expression 
 Peroxiredoxins (Prx) are a group of antioxidants that function by removing cellular 
hydrogen peroxide. There is a significant decrease in Prx-2, -3 and -5 in FECD endothelium 
compared to normal suggesting a reduction in the ability of FECD endothelial cells to resist 
oxidant-induced damage.15  
2.6.8.5 Mitochondria and DNA Damage 
ATP production or utilization may play a role in the pathogenesis of FECD. 
Cytochrome oxidase is a key enzyme in the respiratory chain. There is a reduction of 
cytochrome oxidase activity in the central area of FECD endothelium, along with a 
decreased number of mitochondria.90 
8-hydroxy-2-deoxyguanosine (8-OHdG) is an oxidative DNA damage marker. 
There is an increase in 8-OHdG levels in FECD endothelial cells compared to normals. 
Oxidative DNA damage in FECD co-localizes with mitochondria (Figure 28). There is also 
a co-localization of apoptosis and oxidative DNA damage in FECD endothelium compared 
to normal and pseudophakic bullous keratopathy (PBK) endothelium.13 Normal endothelial 
cells are resistant to oxidative-stress-induced apoptosis ex vivo. While in FECD endothelial 
cells, there is an increase in p53 levels (p53 has many mechanisms of anticancer function, 
apoptosis initiation and genomic stability) leading to increased susceptibility to oxidative-
stress-induced apoptosis (Figure 29). Therefore, p53 is presumed to play a central role in 
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cell death seen in FECD.16  Figure 30 sumarizes the pathogenesis of FECD as proposed by 
Jurkunas et al.13 
 
 
Figure 28: Oxidative DNA damage and its colocalization with mitochondria in FECD 
endothelium. (A) ELISA showing higher concentration of 8-OHdG per nanogram DNA 
from patients with FECD and normal, *p=0.006. (B) In vivo confocal microscope images of 
normal and FECD endothelium. (C) Showing increased immunostaining of FECD 
endothelium with 8-OHdG (green) and its colocalization with mitochondria (red) compared 
with normal endothelium. Nuclei are in blue. Asterisks indicate guttae.13   
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Figure 29: Apoptosis and oxidative DNA damage in normal, FECD and PBK endothelium. 
This figure demonstrates an increased apoptosis (TUNEL in red) and its colocalization with 
oxidative DNA damage (anti-8-OHdG in green) in FECD endothelium. Nuclei are in blue. 
Asterisks indicate guttae.13 
  49 
 
 
Figure 30: Summary of FECD pathogenesis as proposed by Jurkunas et al.13 
2.7 Inheritance 
FECD is an inherited disease that usually follows an autosomal dominant pattern 
with a high degree of penetrance and variable expressivity.91-93 Females are more severely 
affected than males but not more frequently.94 Increased severity in women may also 
suggest a hormonal role in the pathophysiology of FECD. 
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2.7.1 International Committee for Classification of Corneal Dystrophies 
(IC3D) 
The new IC3D classification of corneal dystrophies includes FECD in three 
categories depending on the characterization of the gene defect (Table 3).6, 95 
Category I includes a well-defined corneal dystrophy where both of gene and 
specific mutation have been identified. Early-onset FECD mapped to COL8A2 (FECD1) 
falls in this category.96   
Category II includes a well-defined corneal dystrophy that has been mapped to one 
or more specific chromosomal loci but the gene has not been identified. Familial FECD 
(FECD 2) falls in this category. 
Category III includes a well-defined corneal dystrophy where the chromosomal 
locus has not been identified. A large number of familial FECD cases fall in this category.97  
 
Table 3: Summary of FECD defective genes and their mutations.6  
2.8 Current Treatment 
The management of FECD depends on its clinical stage: 
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Stage I:  treatment is not necessary. 
Stage II: topical hyperosmotic agents (5% NaCl solution) or hairdryer could be used 
to facilitate corneal dehydration.  
Stage III: loosely fit, high water content soft contact lenses could be used to relieve 
pain caused by recurrent erosions.  
Intraocular pressure-lowering agents, even if the intraocular pressure is normal, 
could be used. Carbonic anhydrase inhibitors, however, should be avoided as they may 
interfere with the Na+-K+ATPase pump. There is no evidence that the use of steroids would 
help in FECD.98 
When medical management is no longer adequate, corneal transplantation becomes 
the only available option. The current management is based on the surgical replacement of 
the diseased endothelium with a healthy endothelium from an eye bank donor, either by 
PKP where full thickness of the cornea is replaced or, now more frequently, using a 
DSAEK procedure, where only the diseased posterior part of the cornea is replaced.20 
2.9 Limitations of Current Knowledge and Management of 
FECD 
  Many factors contribute in our lack of knowledge of the mechanism of FECD. 
Most of the studies conducted to investigate the pathogenesis of Fuchs were performed at 
the clinical end-stage due to the infeasibility of obtaining a biopsy of the cornea from an 
asymptomatic patient (at early stages of the disease). FECD spans up to 20 years; the 
timeline of disease is missing. For example, what is the role of the accumulation of 
abnormal DM and of guttae formation in endothelial cell dysfunction and survival? And 
what is the significance of the fibrilar layer in DM? 
Lack of knowledge of FECD pathogenesis along with lack of experimental models 
contributes to the absence of effective medical treatment.  
Surgical management is not perfect either. Corneal endothelial allograft 
transplantation yields a 10% average rate of immunologic rejection (range 0% to 45% for 
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follow-ups ranging from 6 to 21 months).21 There is a 17% cumulative probability of 
endothelial graft rejection at four years in patients with FECD without ocular co-
morbidities. Graft rejection in these eyes is known to result in significant endothelial cell 
losses, thus graft failure.99 
Corneal endothelial tissue engineering may carry a potential solution to these 
problems. By creating an in vitro and in vivo model of the disease, its pathogenesis could be 
better understood and potential treatments could be tested. In addition, transplantation of 
functional TE corneas to the same patient (autograft) would allow the elimination of 
allograft rejection.  
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3 Chapter III:         
 Tissue Engineering of the Corneal Endothelium 
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Human corneal endothelial cells are believed to be incapable of proliferation in vivo. 
They are arrested in the G1-phase of the cell cycle.23 Once cell degenerates for any reason 
(i.e. aging, toxins, trauma or disease) the neighboring cells will enlarge and migrate in order 
to maintain the integrity of the monolayer, leading to a decrease in cell density and, 
eventually, endothelial failure. 
Human corneal endothelial cells retain their capacity of proliferation in vitro in 
response to growth promoting agents,25, 26 which makes tissue engineering of a corneal 
endothelium feasible. The tissue engineering procedure, however, consists of several steps 
including cell isolation, cell culture and tissue carrier. Techniques and materials vary 
greatly between different laboratories. 
The ideal tissue engineered cornea should be nontoxic, free of transmitting diseases, 
genetically stable, immunologically compatible and having long term functioning stability 
and high cell survival rate. It also needs to be compatible with current surgical techniques 
for transplantation. Patients have to obtain superior benefits with this tissue engineered 
graft in order to replace current native graft transplantation. 
In this chapter, I will briefly review corneal endothelial tissue engineering. I will be 
focusing on our laboratory success in isolating and culturing endothelial cells from patients 
with Fuchs endothelial corneal dystrophy. 
3.1 Corneal Endothelial Cell Isolation Techniques 
Risk of contamination of corneal endothelial cell culture with stromal keratocytes is 
a challenge.100, 101 The most common method to overcome this challenge is to peel off 
Descemet’s membrane (DM) (carrying endothelial cells) from its stromal bed. Endothelial 
cells are then detached from DM using either ethylenediaminetetraacetic acid (EDTA), 26, 
102 collagenase,103  trypsin,104 or dispase.105  
The isolation method that we use in our lab is based on Zhu and Joyce technique.26 
For human subjects (i.e. patients with FECD), endothelial cell specimen is obtained as 
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follows: At the time of DSAEK, a blunt-tipped, reverse Sinskey hook is used to score the 
diseased Descemet's membrane (DM), which is then peeled off and removed from the eye 
through a 2.75 mm limbal incision using an angled tying forceps. The anterior chamber 
being maintained by balanced salt solution (BSS; Alcon Canada Inc., Mississauga, ON, 
Canada) irrigation. The specimen is put in Optisol-GS (Bausch and Lomb, Rochester, NY) 
and sent on ice to the laboratory for cell isolation (Figure 31). For PKP, the full thickness 
corneal specimen is sent in Optisol-GS and DM is stripped in the laboratory.  
For eye bank donor corneas (Québec Eye Bank, Montréal, and Banque d’yeux du 
Centre universitaire d’ophtalmologie (CUO), Québec, QC, Canada), endothelial cell 
specimen is obtained as follows: Central Descemet’s membrane is stripped using a circular 
biopsy punch (Acuderm, Dormer Laboratories, Toronto, ON, Canada) and fine forceps.  
Descemet’s membranes are incubated overnight at 37oC in growth medium. After 
centrifugation, they are incubated one hour in 0.02% ethylenediaminetetraacetic acid 
(Sigma, Oakville, ON, Canada) and the loosened cells are gently detached from DM by 
passing several times through a flamed-polished pipet. Cells are then centrifuged and 
resuspended in fresh medium. This isolation method was proposed to avoid fibroblast 
contamination.26  
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Figure 31: Central corneal DM-endothelium of a 58 year-old female with Fuchs endothelial 
corneal dystrophy (A). Higher magnification of the specimen showing multiple guttae and 
pigmentation (arrowheads) (B). Histology of the DM before cell isolation (C) showing 
multiple guttae and a few scarce cells (arrows). This specimen successfully initiated a 
culture. Scale bars: (A) 1 mm, (B) 100 μm, C) 20 μm.30 
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3.2 Corneal Endothelial Cell Culture Methods 
As mentioned before, corneal endothelial cells retain their proliferative capacity 
when isolated and incubated in serum and growth media. Many growth supplements were 
tested in order to enhance the proliferative capacity of the endothelial cells and maintain 
their morphology. Peh et al.106 published a review describing different growth medium 
formulas optimized from different laboratories (Table 4). The goal of adding growth 
supplements is to enhance proliferation and to help maintaining endothelial morphology. 
Author Basal medium  Serum (%) Growth factors and supplements 
Blake et al.107 MEM 10% 5 µg/mL insulin 
5 µg/mL transferrin 
5 ng/mL sodium selenite 
150 µg/mL ECGS 
50 µg/mL gentamicin 
100 U/mL penicillin 
100 µg/mL streptomycin 
0.25 µg/mL amphotericin B 
Yue et al.108 MEM 15% 200 mM glutamine 
2% essential amino acids 
1% nonessential amino acids 
10 µg/mL gentamicin 
1.2 µg/mL amphotericin B 
Miyata et al.109 and 
Amano110 
DMEM 15% 30 mg/L L-glutamine 
2.5 mg/L fungizone 
2.5 mg/L doxycycline 
2 ng/mL bFGF 
Pistsov et al.111 M199 20% 4 mM glutamine 
200 µg/mL ECGS 
100 µg/mL penicillin 
100 µg/mL streptomycin 
Zhu and Joyce26 Opti-MEM-I 8% 20 ng/mL NGF 
5 ng/mL EGF 
20 µg/mL ascorbic acid 
200 mg/L calcium chloride 
100 µg/mL pituitary extract 
50 µg/mL gentamicin 
1Xantibiotic/antimycotic 
0.08% chondroitin sulfate 
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Engelmann and Friedl112, 113 F99 Ham’s F12 
and M199 (1:1 
ratio) 
2%–5% 20 µg/mL ascorbic acid 
20 µg/mL bovine insulin 
2.5 µg/mL transferrin 
0.6 µg/mL sodium selenite 
10 ng/mL bFGF 
Li et al.103 SHEM Ham’s 
F12 and DMEM 
(1:1 ratio) 
5% 0.5% DMSO 
2 ng/mL EGF 
5 µg/mL insulin 
5 µg/mL transferrin 
5 ng/mL selenium 
0.5 µg/mL hydrocortisone 
1 nM cholera toxin 
50 µg/mL gentamicin 
1.25 µg/mL amphotericin B 
Ishino et al.105 DMEM 10% 2 ng/mL bFGF 
50 U/mL penicillin 
50 µg/mL streptomycin 
Choi et al.114 EGM-2 
endothelial 
growth medium 
10% SingleQuots (Lonza, Switzerland) 
consisting: 
VEGF 
EGF  
bFGF  
IGF 
Ascorbic acid  
Hydrocortisone  
Gentamicin  
Amphotericin B 
Table 4: Growth medium supplements used to culture human corneal endothelial cells. 
ECGS, endothelial cell growth supplement; bFGF, basic fibroblast growth factor; NGF, 
nerve growth factor; EGF, epidermal growth factor; DMSO, dimethyl sulfoxide; VEGF, 
vascular endothelial growth factor; IGF, insulin-like growth factor; SHEM, supplemented 
hormonal epithelial medium; MEM, minimum essential medium; DMEM, Dulbecco’s 
Modified Eagle Medium. Modified from Peh et al.106 
We use the formula described by Zhu and Joyce,26 which was optimized for human 
endothelial cell culture. Our growth medium consists of OptiMem-I (Invitrogen, 
Burlington, ON, Canada), 8% fetal bovine serum (HyClone, Logan, UT), 5 ng/ml human 
epidermal growth factor (Austral Biologicals, San Ramon, CA), 20 ng/ml nerve growth 
factor (Biomedical Technologies, Stoughton, MA), 100 µg/ml bovine pituitary extract 
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(Biomedical Technologies), 20 µg/ml ascorbic acid (Sigma), 200 mg/L calcium chloride 
(Sigma), 0.08% chondroitin sulfate (Sigma), 25 µg/ml gentamycin sulfate (Schering, Pointe 
Claire, QC, Canada) and 100 IU/ml penicillin G (Sigma).  
Our laboratory has validated this formula for normal human endothelial cell culture 
and we have demonstrated for the first time that human endothelial cells obtained from 
patients with FECD can be cultured using this formula without the need of transfecting 
oncogenes.30   
We have reported a culture success rate of 62% for FECD endothelial cells and 58% 
for normal endothelial cells. 66% of cultured FECD endothelial cells have an endothelial 
morphology (rounded and slightly elongated cells) while the remaining have fibroblast-like 
morphology (thin and very elongated cells). For normal endothelial cell culture, 42% have 
endothelial morphology (Figure 32). Both cells of endothelial and fibroblastic-like 
morphology express keratins 8 and 18 (K8/18) (Figure 33), confirming the absence of 
contamination with fibroblasts in culture.115  Donor’s old age and presence of fibrillar layer 
of DM are the main factors affecting initiation of endothelial cell culture with an 
endothelial morphology. On the other hand, donor gender, presence of guttae, pigmentation 
and corneal edema, and specimen size do not seem to affect successful culture.  
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Figure 32: Culture of corneal endothelial cells and their morphology. (A-D) Show FECD 
endothelial cells. (E-F) Show normal endothelial cells. (A) Shows endothelial-like 
morphology of a primary FECD (P0) culture. (B) Shows mixed morphology of FECD 
corneal endothelial cells of another primary culture (P0). (C) Shows second-passaged 
FECD cells of the same population in A. (D) Shows third-passaged FECD cells of the same 
population in A and C. The culture formed a monolayer of polygonal cells. (E) Shows 
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culture of normal corneal endothelial cells in P0. (F) Shows confluent third-passaged 
culture of normal corneal endothelial cells. Scale bars 100 μm.30 
 
Figure 33: Keratins 8 and 18 (K8/18) expression. (A-B) Show cultured FECD corneal 
endothelial cells with endothelial (A) and fibroblast-like morphology (B). (C-D) Show 
cultured normal corneal endothelial cells of endothelial morphology (C) and fibroblast-like 
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morphology (D). (E) Shows cultured corneal stromal fibroblasts. (F) Shows native normal 
cornea. K8/18 (red) was expressed in both cultured and native corneal endothelial cells (A-
D, F) and was absent in both cultured and native corneal stromal cells (E-F). Nuclei were 
stained with Hoechst (blue). Scale bars: 50 μm. 
3.3 Endothelial Cell Carriers 
Cultured endothelial cells need a support in order to be transplanted in vivo. Several 
carriers have been proposed. Thin carriers (such as Descemet’s membrane,116 amniotic 
membranes,105 gelatin membranes,117 anterior crystalline lens capsule118  and silk fibroin 
membranes119) are soft and hard to manage. Transplanting them in vivo without damaging 
the fragile endothelial cells is a challenge. More rigid carriers (such as hydrogel lenses120 
and cross-linked collagen121) may not follow the curvature of the host cornea, thus they are 
more susceptible to detach.122 
Native stromal carriers mimic the current native allograft transplantation. However, 
they carry a high risk of contamination with epithelial cells and keratocytes in culture as 
well as a risk of immunological rejection when transplanted in vivo.100 
In order to avoid the undesirable effect of native cell presence, a devitalized stromal 
carrier has been proposed. Elimination of native stromal cells can be performed by one 
freeze (-80°C)/thaw cycle,123 three freeze (-20°C)/thaw cycles (technique used by our 
laboratory)27, 29 or chemically using ammonium hydroxide.102  
3.4 Tissue-Engineered Corneal Endothelium Approaches 
 Restoration of normal vision is the ultimate goal of tissue engineering of a cornea. 
Thus, the transparency outcome of the TE corneas is highly important. In vitro and ex vivo 
assessments usually include tissue integrity, endothelial morphometry and function-related 
protein expression. Beside these characterizations, the in vivo assessments include mainly 
corneal transparency and thickness, which indicate the real functionality of the TE cornea. 
Several approaches have been proposed to tissue-engineer a corneal endothelium:  
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Patel et al.124 used an innovative method where superparamagnetic microspheres 
(SPMs) were incorporated into cultured human endothelial cells. The cells were then 
transplanted into a human anterior segment ex vivo model with the aid of an external 
magnetic field. They showed that the endothelial cells formed a confluent monolayer over 
the bare stroma; however, their attachment was not uniform. A similar successful approach 
was also demonstrated by Mimura et al.125  
Amano et al.126 seeded cultured human endothelial cells on denuded human corneas. 
The TE endothelium aspect was comparable to native cornea (in histology, morphology and 
ultrastructure). The TE endothelium showed active pump function. 
Proulx et al.28 used the self-assembly approach to produce tissue-engineered corneas 
using all three corneal cell types (epithelial, stromal and endothelial cells). Endothelial cells 
formed a monolayer of tightly packed cells well adhered to the TE stroma. The TE 
endothelium expressed function-related proteins. 
Previous studies in our laboratory showed that normal feline corneal endothelial 
cells can be cultured on a devitalized human stromal carrier. The TE cornea showed a 
monolayer of tightly packed polygonal cells well adhered to DM.27 The TE corneal 
endothelium expressed function-related proteins. These TE corneas can retain function and 
maintain corneal transparency when transplanted in the feline eye.29 
Wencan et al.127 used the basement membrane of human amniotic membranes as a 
carrier to transplant cultured feline endothelial cells in the feline animal model. After 
culture, endothelial cells formed a continuous confluent monolayer. Six weeks after 
transplantation, grafts were clear and corneal thickness was slightly greater than that before 
transplantation. 
Koizumi et al.128 used collagen type I carrier to transplant cultured monkey 
endothelial cells in the monkey animal model. Endothelial cells formed a confluent 
monolayer of closely attached hexagonal cells that expressed function-related proteins. 
After transplantation, the graft’s transparency increased and central corneal thickness 
decreased suggesting a functioning TE endothelium. 
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Honda et al.129 used native human corneal disk as a carrier where cultured human 
corneal endothelial cells were seeded and then transplanted in the rabbit model. After 
transplantation, the edema of the TE cornea decreased and transparency recovered 
gradually. The transplanted endothelium expressed function-related proteins. 
 In conclusion, several successful attempts were conducted to tissue-engineer a 
functional corneal endothelium by various approaches. However, none of them used 
dystrophic/diseased corneal endothelial cells. Transplantation of TE allografts would not 
solve the problem of rejection. The ideal graft to avoid rejection is the autogenic graft.  
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4.3 ABSTRACT 
The future of regenerative medicine involves the production of tissues using the 
patient’s own cells. Autologous cells are not rejected by the patient’s immune system and 
are therefore better suited for permanent tissue replacement. Engineering tissues using 
diseased cells, however, is a significant challenge, because autologous engineered tissues 
need to be functional before their implantation back into the patient. The goal of this study 
was to assess the feasibility of engineering a corneal endothelium using the corneal 
endothelial cells excised from eyes of patients with end-stage Fuchs endothelial corneal 
dystrophy (FECD) at the time of their corneal transplantation. Two types of corneal 
endothelium were engineered, namely a corneal endothelium generated from FECD corneal 
endothelial cells and a corneal endothelium generated from healthy eye bank corneal 
endothelial cells. In both cases, cultured corneal endothelial cells were seeded on the 
Descemet’s membrane of a devitalized human stromal carrier. The tissue-engineered 
corneas were kept in culture for 1 to 3 weeks. They were then studied by morphometric 
analyses of flat mounts stained with alizarin red or fixed for histology, transmission 
electron microscopy and immunofluorescence microscopy. Both types of corneal 
endothelium (tissue-engineered from FECD or healthy corneal endothelial cells) formed a 
monolayer of tightly-packed cells that adhered well to Descemet’s membrane. FECD and 
healthy tissue-engineered endothelial cells expressed similar levels of the function-related 
proteins Na+/K+-ATPase α1 and sodium-bicarbonate co-transporter (Na+/HCO3-). They 
similarly expressed keratins 8 and 18 (K8/18) and did not express alpha-smooth muscle 
actin (α-SMA). Clusterin expression was faint and uniform in both groups. To the best of 
our knowledge, this is the first report on the feasibility of engineering a tri-dimensional 
human tissue from diseased cells. Potential applications of this engineered tissue show 
promise for the treatment of this eye blinding disease. 
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4.4 INTRODUCTION  
The cornea is constituted of an epithelium, a stroma and an endothelium. The 
corneal endothelium consists of a monolayer of flatt ened cells facing the anterior chamber 
of the eye.130, 131 Its main role is to maintain corneal transparency by ensuring stromal 
dehydration, a process achieved through ionic pumps (Na+/K+ATPase, Mg2+-ATPase)132  
and ion transporters such as the co-transporter Na+/HCO3-.133 Corneal endothelial cell 
dysfunction results in stromal hydration and loss of corneal transparency, leading to 
blindness.2  
Endothelial failure can result from a number of conditions, the two most frequent 
etiologies being Fuchs endothelial corneal dystrophy (FECD) and surgical traumatism 
(post-cataract surgery complications), which were respectively responsible for 47.7% and 
19.2% of the 23,287 corneal endothelial transplantations performed in the United States in 
2011.48 There are currently no non-surgical therapeutic alternatives to corneal 
transplantation for corneal endothelial failure. Corneal endothelial allograft, however, 
yields a 10% average rate of immune rejection (range: 0% to 45% for follow-ups ranging 
from 6 to 21 months).21 Li et al. recently reported a 17% cumulative probability of 
endothelial graft rejection at four years in patients with FECD without ocular co-
morbidities. Graft rejection in these eyes is known to result in significant endothelial cell 
loss.99  
Tissue engineering offers the option of generating a new and highly functional 
corneal endothelium made from autologous cells, which would allow to circumvent the two 
main causes for endothelial graft failure, namely immune rejection and endothelial cell 
attrition. The challenge with tissue engineering a corneal endothelium starts at the cell 
culture level. In the living eye, corneal endothelial cells are arrested in the G1-phase of the 
cell cycle and do not proliferate.23 When isolated and cultured in the presence of growth 
promoting agents, however, these cells are capable of limited proliferation.24, 26 Our group 
has reported on the successful culture of corneal endothelial cells.28, 134 We have used these 
cultured cells to engineer a corneal endothelium,27 which was shown to be highly functional 
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at one week when transplanted in a living animal eye.29 Engineering a corneal endothelium 
for autologous transplantation also implies harvesting autologous cells to initiate the 
culture. Our group has demonstrated the feasibility of engineering a corneal endothelium 
from a small size endothelial biopsy harvested from healthy feline corneas.100 In the case of 
FECD, the challenge is two-fold, as endothelial cell density is severely decreased and the 
remaining cells are sick. However, preliminary results by our group have shown that the 
central corneal endothelial cells harvested in human patients at the time of corneal 
transplantation for end-stage clinical FECD still retain proliferative capacities.30  
This paper shows the feasibility of engineering a corneal endothelium using corneal 
endothelial cells from patients with end-stage clinical FECD. To the best of our knowledge, 
this is the first report on the characterization of an ocular tissue engineered from diseased 
ocular cells.  
4.5 MATERIALS AND METHODS 
This study was conducted according to our institutions’ guidelines and the 
Declaration of Helsinki. Six specimens from six patients with end-stage clinical FECD 
were used in this study (three women and three men, aged 58 to 77 years, mean ± SD = 68 
± 8 years). The diseased Descemet’s membranes were harvested at the time of corneal 
transplantation, as described previously.30 Native human corneas without endothelial 
diseases (hereafter called “healthy”) and unsuitable for transplantation in human subjects, 
were obtained from our local eye bank (Banque d’Yeux du Centre universitaire 
d’ophtalmologie (CUO)). These healthy corneas were used for immunostaining of native 
corneas (three corneas from two donors, aged 74 and 77), for isolation and culture of 
healthy corneal endothelial cells (two corneas from two donors, aged 47 and 68) and as 
carriers for the engineering of corneal endothelia (ten corneas from ten donors, aged 54 to 
84 years, mean ± SD = 69 ± 10 years).  
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4.5.1 Devitalisation of the Human Stromal Carriers 
The eye bank corneas were devitalized using three freeze-thaw cycles,27 then stored 
at -20°C until used (range: 17 to 620 days, mean ± SD = 88 ± 106 days). On the day of 
reconstruction, they were thawed, rinsed to remove the dead cells, and observed under a 
stereomicroscope (Nikon SMZ800, Mississauga, ON, Canada). Corneas in which 
Descemet’s membrane was detached were discarded. 
4.5.2 Isolation and Culture of Corneal Endothelial Cells from Healthy 
and FECD Corneas 
All corneal endothelial cells were isolated using the technique described by Zhu and 
Joyce (2004).26 Briefly, Descemet’s membranes were peeled off and incubated overnight in 
growth medium at 37°C. After centrifugation, they were incubated 1 h in 0.02% EDTA 
(Sigma, Oakville, ON, Canada), and the loosened cells were detached from the Descemet’s 
membrane by several passes through a flamed-polished pipet. Cells were then centrifuged 
and resuspended in fresh medium consisting of OptiMem-I (Invitrogen, Burlington, ON, 
Canada), 8% fetal bovine serum (HyClone, Logan, UT), 5 ng/mL human epidermal growth 
factor (Austral Biologicals, San Ramon, CA), 20 ng/mL nerve growth factor (Biomedical 
Technologies, Stoughton, MA), 100 μg/mL bovine pituitary extract (Biomedical 
Technologies), 20 μg/mL ascorbic acid (Sigma), 0.08% chondroitin sulfate (Sigma), 25 
μg/mL gentamicin sulfate (Schering, Pointe-Claire, QC, Canada) and 100 IU/mL penicillin 
G (Sigma). Cells were plated on dishes covered with FNC coating mix (containing 
fibronectin, collagen and albumin; Athena Enzyme Systems, Baltimore, MD).  
Population doubling was determined by the common logarithm of the number of 
cells in the growth dishes at the end of a period of growth divided by the number of viable 
cells plated in the growth dishes multiplied by 3.33. 
4.5.3 Tissue-Engineered Human Corneal Endothelium 
Tissue engineering of the corneal endothelium was performed as per our previously 
published protocol.29 Briefly, devitalized human corneas were placed in the bottom of a six-
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well plate, with the denuded Descemet’s membrane facing up. Endothelial cells isolated 
from healthy eye bank corneas (n=3, initial cell seeding of 2.8x105 ± 0.1x104 cells) and 
FECD specimens (n=6, initial cell seeding of 2.0x105 ± 8.2x104 cells) were seeded on top 
of the denuded Descemet’s membrane and allowed to adhere for 4 h before immersion in 
culture medium. They were further cultured for 1 to 3 weeks (healthy corneal endothelial 
cells: from 9 to 16 days, mean ± SD = 11 ± 2 days; FECD corneal endothelial cells: from 8 
to 20 days, mean ± SD = 13 ± 3 days). A flow diagram of the tissue engineering protocol is 
presented in Figure 34. 
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Figure 34: Schematic representation of the tissue engineering protocol. Healthy eye bank 
corneas were devitalized following three freeze-thaw cycles and used as carriers for the 
engineering of a corneal endothelium using cultured cells isolated from FECD specimens. 
The same protocol was also used to engineer a corneal endothelium using healthy cells 
from normal eye bank corneas (not shown). 
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4.5.4 Tissue Fixation 
Each tissue-engineered cornea was divided into four parts. One quarter was used for 
alizarin red staining for endothelial cell density assessments. One quarter was fixed in 3.7% 
formaldehyde (ACP Chemicals, Montreal, QC, Canada) for histology. One quarter was 
embedded in Optimal Cutting Temperature compound (Somagen, Edmonton, AB, Canada), 
frozen in liquid nitrogen and stored at -70°C for ulterior immunofluorescence staining. The 
last quarter was fixed in 2.5% glutaraldehyde and processed for transmission electron 
microscopy. 
4.5.5 Corneal Endothelial Cell Density 
Cell density of the tissue-engineered corneal endothelium was calculated as 
described.29 Briefly, the surface was stained for 45 seconds with the intercellular stain 
alizarin red S (0.2%; Sigma) then rinsed and photographed (Nikon SMZ800). Using the 
KSS-409SP software (version 2.10), endothelial cell densities were determined and 
morphometric analyses were performed. Different fields were randomly selected for each 
tissue-engineered endothelium. The percentage of hexagonal cells was used as an index of 
pleomorphism and the coefficient of variation in cell area was used as a measure of 
polymegethism.67, 135 Data were statistically evaluated with the unpaired student’s t-test 
using the Prism software (version 5.0). P-values less than 0.05 were considered statistically 
significant. 
4.5.6 Histology and Electron Microscopy Analysis 
For histology, the tissue fixed in formaldehyde was processed for paraffin 
embedding. Sections (5 µm) were stained with Masson’s trichrome and analyzed by light 
microscopy. For transmission electron microscopy, the tissue fixed in glutaraldehyde was 
washed in cacodylate buffer, post-fixed in 1% osmium tetraoxide, stained with 0.5% uranyl 
acetate dehydrated in a graded series of ethanol solutions, and embedded in Poly/Bed 812. 
Thin sections were processed and visualized using a JEOL JEM-1230 transmission electron 
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microscope (Tokyo, Japan) at 80 kV. Thickness measurements were made using 
AxioVision 4.8.1 (Carl Zeiss, Toronto, ON, Canada). 
4.5.7 Indirect Immunofluorescence Analysis 
Indirect immunofluorescence was performed as previously described.29 
Cryosections (5 μm) were fixed for 10 minutes at -20°C using acetone (90%, EMD, 
Mississauga, ON, Canada) and immunostained with anti-Na+/K+-ATPase α1 (clone 9A-5; 
Sigma), a rabbit anti- Na+/HCO3- (Abcam, Cambridge, MA), and a guinea pig anti-
cytokeratin 8/18 (clone GP11; ARP, Waltham, MA) as primary antibodies. Others 
cryosections were fixed for 10 minutes at -20°C using methanol (100%, Fisher Scientific, 
Ottawa, ON, Canada) and immunostained with a mouse anti-alpha smooth muscle actin (α-
SMA; clone 1A4, Dako, Burlington, ON, Canada). For clusterin immunostaining, 
cryosections were fixed for 10 minutes at -20°C using ethanol (99%, Commercial Alcohols, 
Brampton, ON, Canada), permeabilized with Triton-PBS 1% (v/v) for 10 minutes and 
immunostained with a mouse anti-clusterin-α/β (H-330, Santa Cruz Biotechnology, Santa 
Cruz, CA). Goat anti-guinea pig, donkey anti-mouse and chicken anti-rabbit IgG antibodies 
conjugated with Alexa 594 (Invitrogen) were used as secondary antibodies. Sections were 
incubated with antibodies diluted in phosphate buffered saline containing 1% bovine serum 
albumin (Sigma), at room temperature for 2h (for clusterin) or 45 min (for all other primary 
antibodies) and 30 min for secondary antibodies. Negligible background was observed for 
controls (primary antibodies omitted). Cell nuclei were counterstained with Hoescht 
reagent 33258 (Sigma). Fluorescence was observed using a Nikon Eclipse TE-2000U 
inverted microscope. 
4.6 RESULTS 
4.6.1 Isolation and Culture of Healthy and FECD Corneal Endothelial 
Cells 
Figure 35 shows the central Descemet membrane taken from a healthy cornea 
(Figure 35A) possessing a monolayer of hexagonal cells (Figure 35B) overlying a thin and 
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uniform Descemet’s membrane (Figure 35C). FECD specimens showed the classic signs of 
this dystrophy, including the presence of numerous excrescences (guttae) and pigmentation 
(Figure 35A-C). Histology of the Descemet’s membranes rarely showed the presence of 
endothelial cells, a result of both the dystrophy and the surgery necessary for their retrieval.  
However, the few endothelial cells that remained were able to generate a cell culture (Fig. 
3).30(Figure 36).30 
At primary culture, some of the isolated FECD cells showed cytoplasmic pigment 
granules (Figure 36D).  These pigmented cells did not proliferate, and no pigmented cells 
were found in any of the passaged cultures (Figure 36E-F).  After reaching confluence, 
FECD (Figure 36E-F) and healthy corneal endothelial cells (Figure 36B-C) adopted the 
typical endothelial polygonal morphology.  
FECD and healthy corneal endothelial cells also showed similar cell counts and 
population doubling times. After one passage, the mean FECD cell count was 4.7x105 ± 
3.1x105 cells (range: 3.3x104 to 1.1x106 cells), corresponding to a 2.1 population doubling 
in 4 ± 1 days. The mean cell count for healthy corneal endothelial cells was 5.0x105 cells ± 
2.2x105 cells (range: 3.0x105 to 7.0x105 cells), corresponding to a 1.9 population doubling 
in 5 ± 1 days.  
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Figure 35: Descemet’s membrane from healthy Eye bank corneas and from patients with 
Fuchs endothelial corneal dystrophy. A) Central Descemet’s membrane taken from a 
healthy Eye bank cornea. B) Higher magnification of (A) shows the corneal endothelium as 
well as some areas of endothelial damage. C) Histology cross-section shows a uniform 
Descemet’s membrane along with a monolayer of corneal endothelial cell. D) Specimen 
from a patient with Fuchs endothelial corneal dystrophy upon receipt, as seen through a 
stereomicroscope. E) Higher resolution of the specimen shown in (A). Note the presence of 
multiple guttae and pigmentation. F) Histology of a Descemet’s membrane from a patient 
with Fuchs endothelial corneal dystrophy. Note the thickened Descemet’s membrane and 
the presence of excrescences (guttae) typical of this dystrophy (star). The trichrome 
Masson’s staining gives a purple coloration to cells and a blue coloration to collagen. Scale 
bar: (A, D) 1 mm, (B, E) 100 μm, (C, F) 20 µm. 
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Figure 36: Culture of corneal endothelial cells from healthy corneas and from patients with 
clinical end-stage Fuchs endothelial corneal dystrophy. A) Sub-confluent corneal 
endothelial cells in primary culture (P0). B) Confluent third-passage endothelial cells from 
healthy cornea. C) Higher magnification of (B) shows that endothelial cells form a 
monolayer of polygonal cells. D) FECD corneal endothelial cells in primary culture (P0). 
Arrow shows a pigmented cell with blebs, a characteristic sign of apoptosis. E) Confluent 
third-passage corneal endothelial cells from FECD. F) Higher magnification of (E) shows 
that confluent FECD cells also adopt the typical endothelial polygonal morphology.  Scale 
bars: 100 μm. 
4.6.2 Tissue-Engineered Corneal Endothelium 
The freeze-thaw cycles allowed destruction of all native cells (Figure 37A). 
Endothelial cells cultured on the devitalized carrier entirely resurfaced the denuded 
Descemet’s membrane, forming a monolayer of tightly packed cells (Figure 37B-C).  
 Alizarin red confirmed the complete coverage by polygonal cells (Figure 38A and 
B). Some small intercellular gaps were present. Cell density in the tissue-engineered FECD 
corneal endothelium was 581 ± 241 cells/mm2 (range: 235 to 1038 cells/mm2, n=17 counts 
of 6 tissue-engineered corneas) whereas the corneal endothelium tissue-engineered with 
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healthy cells was at 782 ± 63 cells/mm2 (range: 689 to 868 cells/mm2, n=6 counts of 2 
tissue-engineered corneas) (Figure 38C). The difference in cell density between the two 
groups was not statistically significant (p-value = 0.0598). The percentage of 6-sided cells 
and the coefficient of variation in cell area were also similar between the two groups 
(respective p-values of 0.5056 and 0.3564). The tissue-engineered FECD corneal 
endothelium contained cells with a higher average cell area; however, the difference was 
not statistically significant (p-value = 0.0581). 
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Figure 37: Histology cross-sections. Trichrome Masson’s staining. This staining gives a 
purple coloration to cells and a blue coloration to collagen. A) Devitalized human cornea 
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before cell seeding. Note the absence of cells in the stroma (s) and on Descemet’s 
membrane (DM). B) Corneal endothelium tissue-engineered using cells from patients with 
Fuchs endothelial corneal dystrophy. C) Corneal endothelium tissue-engineered using 
healthy cells from an eye bank cornea. D) Native human eye bank cornea. Scale bar: 20 
μm. 
 
Figure 38: Endothelial cell coverage and density. A, B) Alizarin red staining of an 
endothelium tissue-engineered with FECD (A) and healthy (B) corneal endothelial cells. 
High cell coverage of the carrier is shown, with only narrow acellular areas stained with 
alizarin red between adjacent cells, indicating still-incomplete attachment between cells. C) 
Morphometric analysis. Alizarin red images were analysed using the KSS-409SP software 
available in specular microscopes used in Eye banks, which calculates cell density, cell 
morphology, cell area, standard deviation of cell area and coefficient of variation. Results 
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are presented as mean ±SD. TE: Tissue-engineered, FECD: Fuchs endothelial corneal 
dystrophy, SD: standard deviation of cell area, CV: coefficient of variation. Scale bar: 100 
μm. 
4.6.3 Ultrastructure 
A normal Descemet’s membrane is thin and uniform and composed of an anterior 
banded layer and a posterior non-banded layer (Figure 39A). One typical finding in late-
stage FECD is the presence of an abnormal fibrillar layer in Descemet’s membrane (Figure 
39B and C). No fibrous material was deposited by the endothelial cells on top of the native 
Descemet’s membrane Figure 39E and F). Transmission electron microscopy showed a 
single layer of endothelial cells in close proximity to Descemet’s membrane in the native 
(Figure 39D) as well as in both types of engineered tissues (Figure 39E and F). The mean 
thickness of the engineered FECD endothelium was 3.2 ±0.9 µm (range: 1.4 µm to 4.8 µm; 
n=30 counts of 5 tissue-engineered corneas), and the mean thickness of the engineered 
endothelium using healthy cells was 4.7 ±1.3 µm (range: 3.0 µm to 6.6 µm; n=12 counts of 
2 tissue-engineered corneas). Lysosomes, mitochondria, rough endoplasmic reticulum and 
Golgi apparatus were observed in both types of tissue-engineered corneal endothelium. 
Cells were in close proximity to each other (Figure 39G). Small intercellular gaps were 
sometimes observed between neighbouring cells (Figure 39H and I).  
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Figure 39: Ultrastructure. A) The Descemet’s membrane of a healthy Eye bank cornea is 
composed of an anterior banded layer (ABL) and a posterior non-banded layer (PNBL). B) 
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Transmission electron microscopy image of a late-stage FECD Descemet’s membrane 
showing the presence of two abnormal layers, the posterior banded layer (PBL) as well as a 
thick fibrillar layer (FL). C) Higher magnification of the fibrillar layer. D) Transmission 
electron microscopy image of the endothelium of a native human eye bank cornea. E) 
Transmission electron microscopy image of a corneal endothelium tissue-engineered using 
cells from a healthy cornea. F) Transmission electron microscopy images of a corneal 
endothelium tissue-engineered using cells from a FECD specimen. Rough endoplasmic 
reticulum (RER) and mitochondria (M) are easily visible. G-I) Cell-cell junctions in a 
corneal endothelium engineered using healthy cells (G) or FECD cells (H-I). Intercellular 
gaps where sometimes observed between cells (arrows). Scale bars: (A, B) 5 μm, (C) 1 µm, 
(D-I) 0.5 μm.  
4.6.4 Endothelial Phenotype 
Both types of tissue-engineered corneal endothelial cells expressed keratins 8 and 
18 (K8/18). Expression was stronger in engineered tissues than in native corneas (Figure 
40C). Absence of α-SMA was also noted in both engineered and native corneal 
endothelium (Figure 40). 
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Figure 40: Keratins 8 and 18 (K8/18) and α-smooth muscle actin (α-SMA) protein 
expression. Immunofluorescence staining (red) of K8/18 (A, C, E) and α-SMA (B, D, F) in 
a corneal endothelium tissue-engineered using cells from FECD corneas (A, B), in a 
corneal endothelium tissue-engineered using cells from a healthy cornea (C, D), and in a 
native human eye bank cornea (E, F). Nuclei are counterstained with Hoechst (blue). The 
corneal endothelium is detached from Descemet’s membrane in C and D. DM: Descemet’s 
membrane. Scale bar: 20 μm. 
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4.6.5 Function-Related Proteins 
As shown in Figure 41, Na+/K+-ATPase α1 protein expression was localized to the 
cell membrane. Expression was more intense in the native cornea than in the engineered 
tissues. Na+/HCO3- protein expression was diffuse, uniform and found throughout the cell. 
This co-transporter’s expression had a similar intensity in engineered and native tissues.   
 
Figure 41: Na+/K+-ATPase α1 and Na+/HCO3- protein expression. Immunofluorescence 
staining (red) of Na+/K+-ATPase α1 (A, C, E) and Na+/HCO3- (B, D, F) in a corneal 
endothelium tissue-engineered using cells from a FECD specimen (A, B), in a corneal 
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endothelium tissue-engineered using cells from a healthy cornea (C, D), and in a native 
human eye bank cornea (E, F). Nuclei are counterstained with Hoechst (blue). DM: 
Descemet’s membrane. Scale bar: 20 μm. 
4.6.6 Clusterin Expression 
Immunostaining of the glycoprotein clusterin was also performed (Figure 42). A 
faint, uniform clusterin staining was present in the cytoplasm of engineered and native 
corneal endothelial cells.  
 
Figure 42: Clusterin protein expression. Immunofluorescence staining (red) of the 
glycoprotein clusterin in a corneal endothelium tissue-engineered using cells from a FECD 
specimen (A), in a corneal endothelium tissue-engineered using cells from a healthy cornea 
(B), and in a native human eye bank cornea (C). Nuclei are counterstained with Hoechst 
(blue). The corneal endothelium is detached from Descemet’s membrane in all three 
images. Scale bar: 20 μm. 
4.7 DISCUSSION 
In this study we demonstrated the feasibility of engineering a human corneal 
endothelium using cultured cells from healthy and FECD corneas seeded on devitalized 
tridimensional corneal carriers. We showed that the two types of corneal endothelium 
engineered either from FECD or from healthy human endothelial cells formed a regular 
monolayer of tightly-packed polygonal cells that adhered well to the Descemet’s membrane 
carrier. The expression of K8/18 and lack of expression of α-SMA confirmed the corneal 
endothelial nature of these cells and the absence of stromal fibroblasts that can sometimes 
contaminate endothelial cell cultures.115 In both groups (tissue-engineered from FECD or 
healthy cells), endothelial cells expressed the function-related proteins Na+/K+-ATPase α1 
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and Na+/HCO3-. They also showed similar expression levels of clusterin, a glycoprotein 
previously reported to be upregulated in FECD.14, 75 No deposition of fibrillar material was 
observed ultrastructurally under the corneal endothelium engineered using FECD cells. 
The corneal endothelia engineered with healthy and FECD cells were similar at all 
levels analyzed (morphology, cell density, ultrastructure, protein expression). The lack of 
indicators of FECD in vitro could be explained by a number of reasons: i) Pigment 
granules: The presence of pigment granules within endothelial cells is typically found in 
FECD.68, 136 There are no reports on corneal endothelial cells being able to synthesize 
pigment granules, and in vitro formation of pigment granules was not observed in this 
study.  It has previously been proposed that the pigments granules found in the endothelial 
cells come from phagocytized pigment granules originating from the iris pigment 
epithelium.137 The absence of pigments in the tissue-engineered endothelium could simply 
be explained by the absence of an active source of pigments, such as the iris epithelium. ii) 
Cell selection: Cell culture may have induced selection of the healthiest cells or the ones 
less affected by the disease. In the native corneal endothelium, K8/18 is not expressed by 
all cells115 and its level of expression varies between cells, as seen in Figure 40E. K8/18 
expression was higher in cultured cells (Figure 40A and C) than in the native tissue, 
suggesting that K8/18-expressing cells were favored by cell culture. Furthermore, FECD 
cultures presented a higher rate of cell apoptosis than the healthy cells in the early culture 
stages, especially among pigmented cells, suggesting early attrition of the most severely 
diseased cells in favor of the most robust cells. iii) Culture time: FECD is a slowly 
progressive corneal disease that becomes clinically evident in adults over age 40.136 In this 
study, characterization of the FECD cells was performed after 1 to 3 weeks of culture, 
which may not have been long enough to observe FECD pathogenesis. iv) Dynamic in vivo 
conditions: Intraocular pressure and flow of aqueous humor, which are absent in our in 
vitro culture conditions, may be required for the development of FECD pathogenesis. v) 
Oxidative stress: Previous studies have shown that FECD cells are more susceptible to 
oxidative stress-induced apoptosis than normal cells.13, 16 In our culture conditions, the 
growth media contained antioxidants (serum, ascorbic acid) and medium was changed three 
times a week to remove oxygen reduction products generated by normal respiratory 
  88 
 
metabolism. Absence of induced acute oxidative stress (by adding reactive oxygen species 
such as hydrogen peroxide for example) in our tissue-engineered model may also explain 
the similarity between healthy and FECD tissue-engineered corneal endothelia. vi) Healthy 
Descemet’s membrane: In FECD, Descemet’s membrane’s structure is abnormal. It is 
thicker, with additional abnormal layers, thick excrescences (guttae) and striated bodies.30, 
66, 68-71 Descemet’s membrane is secreted by corneal endothelial cells throughout life and 
secretion of an abnormal Descemet’s membrane would result from endothelial dysfunction. 
However, cell-extracellular matrix signals interact both ways (inside-out signaling) and the 
abnormal Descemet’s membrane could send signals to the endothelial cells that further 
contribute to the pathology. Consequently, removing the endothelial cells from the diseased 
Descemet’s membrane and seeding these cells on a healthy Descemet’s membrane may 
facilitate restoration of a healthier corneal endothelial phenotype.  
Devitalized eye bank corneas have been previously used by our laboratory for the 
engineering27 and the transplantation29 of an allogeneic corneal endothelium to show its 
short-term functionality. This living model will allow the comparison of the in vivo 
functionality of the human tissue-engineered corneal endothelium engineered using both 
healthy and FECD cells.  The long-term goal would be to use these engineered tissues to 
replace the patient’s dysfunctional endothelium.  Corneal transplantation is never 
performed in both eyes at the same time. FECD is a bilateral often asymmetrical disease,2, 3, 
5, 6 which increases even more the delay between surgeries in the first and second eyes. 
Cells harvested at the time of the first surgery could be cultured and frozen until needed for 
the second eye or if a regraft is required in the first eye. A technique of corneal biopsy 
could also be developed in order to apply this technique to the first eye. A biopsy 
constitutes a realistic approach knowing that a FECD specimen as small as 2 mm2 is 
sufficient to generate enough cells to engineer a fully endothelialized corneal button. 30 
The successful engineering of a tissue using dystrophic cells also paves the way for 
in vitro pharmacologic testing or gene therapy treatments, in order to engineer healthy 
tissues that could be transplanted back into the patient.  
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5 Chapter V:        
 Animal Models and Corneal Transplantation 
Techniques (The Second Objective: DSAEK in the 
Feline Model)  
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5.1 Animal Models 
Transplanting the tissue-engineered endothelium in vivo allows the ultimate 
confirmation of its functionality. The choice of an animal model depends on the anatomical 
and physiological similarities to humans, per and post transplantation challenges, as well as 
model availability and hosting costs. 
High availability, low cost and easy handling are the main advantages of mouse, rat 
and rabbit models. On the other hand, small eye size of mouse and rat and the capacity of 
rabbit endothelial cells to proliferate in vivo138-140 limit their use in the in vivo assessment of 
tissue-engineered corneas. The pig model is characterized by its anatomical and 
physiological corneal similarities to humans.100 It is also highly available. However, 
previous studies in our laboratory demonstrated that penetrating keratoplasty in the pig 
model is challenging and shows suboptimal functional results.141 The monkey model is 
considered very close to the human model.100 It has been used to host tissue-engineered 
corneas that showed optimal functional results.122, 142-144 However, limited availability and 
high hosting cost of this model in North America limit its use. 
The feline model is a well-established model for the assessment of new surgical and 
medical managements involving the cornea. It has been used in comparative microscopic 
studies of the corneal anatomy,145 constructing tissue-engineered corneal endothelium on a 
devitalized human cornea,27 transplanting cultivated corneal endothelial cells on the 
basement membrane of human amniotic membrane,127 devising new preservation models 
for the corneal grafts,146 assessing rejection mechanisms120, 147, 148 and assessing innovative 
methods that would halt corneal rejection.149, 150  Like in humans,23, 24 feline corneal 
endothelial cells do not replicate in vivo,138, 151, 152 contrary to regenerative corneal 
endothelial cells of animals such as rats 153 and rabbits.138-140 Mechanisms of corneal 
endothelium repair by enlargement and migration of cells appear to be the same in cats138, 
152, 154 and in humans.2, 155, 156 Moreover, human and cat exhibit morphological similarities, 
suggesting that developments in tissue-engineered corneal endothelium in the feline model 
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would be readily transferable to human. Some of the comparable particularities, in human 
and cat respectively, are the endothelial cell counts (between 3022-3464 157-159 and 2300-
2900 145, 151, 160-162 cells/mm2), the endothelial cell area (between 317-324 157, 159 and 348-
357 159, 161 μm2) and the central corneal thickness (between 534-564 163, 164 and 545-650 145, 
162, 165, 166 μm). The large corneal diameter of the cat’s cornea (15.5-18160, 167 mm) permits 
full size grafts, using the same instrumentation and techniques as for human subjects. These 
large grafts also yield large amounts of tissue for extensive postmortem analyses.  
Xenografts are well tolerated and the human-to-cat xenograft model of corneal 
transplantation demonstrated endothelial cell loss and other clinical findings similar to 
human allografts.146, 148 However, the feline model is less available and more expensive 
than other models (such as pig, rat and rabbit). For posterior lamellar keratoplasty, the 
feline model is relatively intolerant to air in the anterior chamber,168 and large corneal 
diameter relatively limit intraocular maneuvers during surgery.  
5.2 Transplantation Techniques in the Feline Model 
The ideal surgical technique to transplant a tissue-engineered corneal endothelium is 
characterized by minimal trauma to the newly-made endothelium, quick rehabilitation and 
less postoperative complications (i.e. intraocular inflammation) that could affect the clinical 
outcomes. 
5.3 Penetrating Keratoplasty (PKP) 
Penetrating keratopasty (PKP) (full thickness transplantation) is a well-established 
procedure in the feline model.127, 169, 170 PKP, however, has undesirable complications. The 
sensory innervations of the graft is severed over 360 degrees by the full thickness cut, 
thereby resulting in poor healing of anaesthetized corneas. Suture-related problems are 
numerous. As these sutures loosen, they become exposed and leave the graft amenable to 
infection, ulceration, vascularization and rejection. Full thickness vertical wounds are 
unstable. Indeed, graft dehiscence can occur with minor trauma in as late as several years 
after surgery.  
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In 2009, Proulx et al.29 reported the first evidence that cultured endothelial cells 
seeded on a devitalized stromal carrier can recover an active pump function and can restore 
and maintain normal corneal thickness and crystal-clear transparency over a 7-day 
observation period after transplantation using a PKP technique in the living feline model. 
Eighteen cats were enrolled in the study: eleven cats received tissue-engineered allogeneic 
grafts; one cat received autologous native graft; three cats received allogeneic native grafts; 
one cat received xenogeneic human native graft; two cats received stromal carrier only 
(without endothelial cells). PKP surgery was uneventful in all cases. Nine of the 11 tissue-
engineered grafts and all native grafts were clear 7 days after PKP. One of the unclear 
tissue-engineered grafts had an almost complete detachment of Descemet’s membrane, 
which was noticed at the time of surgery. The other unclear graft had a positive vitreous 
pressure during surgery and intra-operative formation of fibrin membrane strands. The 
postoperative follow-up had also more inflammatory reaction than usually observed, with 
fibrin participates on both graft and recipient. Anterior chamber was calm except a mild 
and transient flare, a few cells, and a fine fibrin membrane residual from surgery in seven 
cases. Neither corneal neovascularization nor immunologic reaction was observed in any 
graft during the observation period. 
5.4 Descemet’s Stripping Automated Endothelial Keratoplasty 
(DSAEK)    
The philosophy of lamellar keratoplasty is to replace only the diseased tissue while 
leaving the healthy tissue in place for greatest functional outcome. In 1998, Gerrit Melles 
described the first experimental corneal endothelial keratoplasty.171, 172 In 2000, Mark Terry 
performed the first posterior keratoplasty in the United States.173, 174 Since then, DSAEK 
became the most popular technique for posterior lamellar transplantation, as confirmed by 
the Eye Bank Association of America (10-fold increase from 2005 to 2007).175 
The remarkable advantages of DSAEK over PKP include: preservation of the host 
corneal surface, with no incisions or sutures; elimination of suture-related complications, 
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rendering a corneal surface that is smoother and almost astigmatism-free; faster wound 
healing and earlier refractive stability with no need for suture removal.  
5.4.1 GOAL 
The goal of this study was to assess the feasibility of DSAEK in the feline model 
(unpublished data). The conclusion of this study determines and justifies the surgical 
technique that is used to transplant the tissue-engineered FECD grafts.   
5.4.2 MATERIALS AND METHODS  
All experiments were conducted in accordance with the Declaration of Helsinki. 
The research protocols were approved by the Committee for Animal Protection of the 
Maisonneuve-Rosemont Hospital (Montreal, QC, Canada). 
Five healthy animals were obtained from a certified supplier. Ophthalmic 
examination included slit lamp examination (Haag-Streit, Bern, Switzerland), intraocular 
pressure measurement with a hand held veterinary tonometer (Tonovet, TV01; Tiolat Oy, 
Helsinki, Finland) and central corneal pachymetry (Ultrasound Pachymeter SP 3000; 
Tomey, Nagoya, Japan). One eye per animal was randomly assigned to surgery.  
One cat received a tissue-engineered (TE) cornea using allogeneic endothelial cells 
(case 1). One cat received a tissue-engineered cornea using autologous endothelial cells 
(case 2). Three cats received a xenogeneic human native cornea (cases 3, 4 and 5). 
Functional outcome was assessed for 7 days. 
Corneal tissue engineering was performed as described previously.27 Briefly, feline 
corneal endothelial cells were isolated and cultured. Native human corneas unsuitable for 
transplantation in humans were used as a carrier. These human corneas were devitalized 
through three freeze -20oC/thaw cycles. The carrier was seeded with the cultured feline 
corneal endothelial cells and cultured for 2-3 weeks to allow the reconstruction of a 
compact endothelial monolayer.  
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5.4.2.1 Surgery  
Preoperative pharmacological dilation of the pupil was achieved using tropicamide 
1% (Mydriacyl, Alcon Canada, Mississauga, Canada), phenylephrine 2.5% (Mydfrin, 
Alcon Canada, Mississauga, Canada), and cyclopentolate (Cyclogyl minims, Chauvin, 
Kingston-Upon-Thames, England) 1 drop of each every 5 minutes.  
Surgeries were performed under general anesthesia. Anesthesia was induced and 
maintained by inhalation of 4-5% and 2% of Isoflurane, respectively. Atracurium (0.25 
mg/kg, followed by 0.1 mg/kg every 20–30 minutes as needed) was used to induce 
paralysis of the extraocular muscles as well as to prevent the third eyelid prolapse. The 
ocular area was disinfected with a 0.5% Povidone-Iodine solution (Proviodine solution 1%, 
Rougier Pharma, Ratiopharm, Canada), along with one drop being added to the inferior 
fornix. Lieberman lid speculum was inserted. 
A limbal 2.5 mm incision was made at the limbus and the anterior chamber was 
filled with viscoelastic (Healon, AMO, Santa Ana, CA). The recipient bed was prepared by 
the stripping of Descemet’s membrane and its endothelium176 and the viscoelastic agent 
was rinsed with BSS. The donor button was then cut with a semi-automated microkeratome 
(ALTK-Cbm, Moria, Antony, France) using a 300 micron foot-plate and a Hannah Punch 
(Moria, Antony, France). A drop of Healon was added on the endothelial surface of the 
posterior lamellar graft, which was then folded in two, in a proportion of 60% top and 40% 
bottom and inserted in the anterior chamber through the 5 mm limbal incision. The graft 
was centered using a reversed Sinsky and stabilized against the recipient bed using an air 
bubble for 30 minutes. The endothelial pump of the newly transplanted endothelium 
allowed the donor disk to adhere to the recipient cornea, thus eliminating the need for 
corneal sutures. The air bubble was then totally removed since the feline model is relatively 
intolerant to air in the anterior chamber.168 
5.4.2.2 Postoperative Management 
Following surgery, all animals received dexamethasone (1.2 mg in 0.3 ml), 
tobramycin (10 mg in 0.25 ml) and cefazolin (55 mg in 0.25 ml) in the form of 
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subconjunctival injections, and tobramycin 0.3% and dexamethasone 0.1% ointment 
(Tobradex, Alcon). An Elizabethan collar was gently tied around the animal’s neck to 
protect the operated eye. Animals were examined daily following surgery to check for graft 
transparency, signs of infection, inflammation, wound dehiscence or other complications. 
5.4.3 RESULTS 
5.4.3.1 Surgery 
Stripping of Descemet’s membrane was challenging. The strong adherence of DM 
to the underlying stroma, especially at the center of the cornea, made it impossible to 
detach the DM and endothelial layers as a single unit. DM adherence was such that pulling 
on it induced significant traction and distortion to the entire cornea with subsequent severe 
corneal edema. Surgical manoeuvres were limited in general by the depth of the anterior 
chamber and the steepness of the corneal curvature in the feline eye. Rapid and severe 
fibrin formation was noticed filling the entire anterior chamber. The fibrin strands 
condensed and attached firmly to the graft once inserted, which made graft unfolding after 
insertion, air bubbling and graft-to-host attachment more challenging and traumatic than 
when DSAEK is performed in humans.  
5.4.3.2 Clinical Outcome 
5.4.3.2.1 DSAEK case 1 (TE cornea using allogeneic endothelial cells): 
Seven days after transplantation, graft was semitransparent with evident epithelial 
and stromal edema. Recipient stromal edema with intra-stromal haemorrhage was observed 
between the limbic wound and the graft. Central corneal thickness was impossible to 
measure. Mild cells and flare were observed in the anterior chamber along with fibrin 
strands attaching to the graft’s edge (Figure 43). 
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Figure 43: First DSAEK case; Slit lamp photos seven days after transplantation (final 
exam) showing semitransparent graft, recipient edema with intra-stromal haemorrhage 
(star) and fibrin strands attaching to the edge of the graft (arrow) (A); and graft edema (B). 
5.4.3.2.2 DSAEK case 2 (TE cornea using autologous endothelial cells): 
Four days after transplantation, graft was opaque with evident epithelial and stromal 
edema. An 80% graft detachment was observed. Cells (+3) and flare (+3) were observed in 
the anterior chamber along with fibrin strands attaching to the graft (Figure 44). 
 
Figure 44: Second DSAEK case; Slit lamp photos four days after transplantation (final 
exam) showing opaque graft with stromal edema (A), graft detachment (red arrow) with 
fibrin attaching to the graft (white arrow) (B). 
It’s possible that fibrin strands pulled the graft when they condensed and contracted 
causing graft detachment.  
A B
A B 
  98 
 
5.4.3.2.3 DSAEK case 3 (xenogeneic human native cornea): 
Intracameral formation of fibrin was observed postoperatively and it was directed to 
the edge of the graft where was the naked stroma of the donor. Four days postoperatively, 
subconjunctival betamethazone (3mg/0.5ml) and intracameral recombinant tissue 
plasminogen activator (rtPA) (150µg/0.3ml) were injected in order to digest the existing 
fibrin. Seven days after transplantation, the graft was clear. Central corneal thickness was 
742 µm. Graft was fully attached to the stromal bed. Cells (+3) and flare (+3) were 
observed in the anterior chamber along with residual particles of fibrin attaching to the 
graft’s borders (Figure 45). 
 
Figure 45: Third DSAEK case; Slit lamp photos: (A-B) four days after transplantation 
showing fibrin formation attached to the edge of the graft (red arrow). (C-D) Seven days 
after transplantation (final exam) showing clear graft with residual digested fibrin (white 
arrow) after rtPA injection. 
A B 
C D 
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This case showed that rtPA injection yielded a relatively successful dissolve of 
fibrin strands allowing better clinical outcomes. 
5.4.3.2.4 DSAEK case 4 (xenogeneic human native cornea): 
One day post transplantation, the graft was partially detached and severe recipient 
corneal edema was observed leading to opaque cornea. Severe intraocular inflammation 
was seen. Fibrin was attached to the graft posteriorly. Two days post transplantation, the 
cornea was totally opaque. The graft dropped in the anterior chamber inferiorly. Corneal 
thickness was over device range of measurement (Figure 46). 
 
Figure 46: Fourth DSAEK case; Slit lamp photos one (A) and two (B) days after 
transplantation showing opaque cornea with severe stromal edema. Graft detachment with 
fibrin attaching to the graft was observed (red arrow). 
The cause of severe intraocular inflammation was unclear. It’s possible that fibrin 
strands caused graft detachment, which in turn increased the inflammatory reaction. 
5.4.3.2.5  DSAEK case 5 (xenogeneic human native cornea): 
Four days after transplantation, the graft was clear and attached. Central corneal 
thickness was 923 µm. Moderate fibrin was seen attaching to the edge of the graft. Seven 
days after transplantation, the graft was crystal clear and attached. Central corneal thickness 
was 692 µm. Multiple dendritic ulcers were observed. Moderate fibrin was seen (Figure 
47). 
A B 
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Figure 47: Fifth DSAEK case; Slit lamp photos: (A-B) four days after transplantation 
showing clear graft and fibrin formation attached to the edge of the graft (red arrow). (C-D) 
Seven days after transplantation showing clear graft with dendritic ulcers (white arrow). 
This case showed an optimal clinical outcome without any unusual intervention.  
5.4.4 DISCUSSION 
Although DSAEK has replaced PKP in the treatment of endotheliopathies in 
humans, few studies have reported DSAEK in the living animal.129, 142 To the best of my 
knowledge, this is the first study that assesses the feasibility of DSAEK in the feline model.  
Honda et al.129 investigated the feasibility of DSAEK using cultured human corneal 
endothelial cells (HCECs) in the rabbit model. Fourteen rabbits were enrolled in the study. 
They were divided into 2 groups:  
A B 
C D 
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- Seven rabbits received a cultured-graft DSAEK group (c-DSAEK) in which a 
stromal disc with cultured HCECs was transplanted. 
- Seven rabbits received a stromal disc without HCECs (control group).  
Corneal edema developed after surgery in both groups. The edema decreased and 
transparency recovered gradually in the c-DSAEK group, whereas the edema persisted for 
28 days in the control group. Honda et al.129 demonstrated a slow recovery of the cDSAEK 
group over 4 weeks of observation, so DSAEK could be reliable in the medium and long 
term. However, his figure showing a slit lamp photo of a graft of cDSAEK group didn’t 
demonstrate a thin and clear graft 21 days after transplantation (Figure 48B). Furthermore, 
how the stromal disc without endothelial cells was hold in its place without being detached 
raises a big question mark.  
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Figure 48: Descemet stripping automated endothelial keratoplasty (DSAEK) in the rabbit 
model. Slit lamp photo of the cultured-graft (DSAEK) group at day 1 after surgery (A), the 
DSAEK graft attached to the posterior surface of the cornea and corneal edema persisted.  
A 
B 
C 
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At day 21 after surgery, corneal edema was less severe in the cultured-graft DSAEK group 
(B) than in the control group (C).129 
In our study, although DSAEK technique requires a learning curve, surgery was 
technically difficult to perform in the feline eye. Reaching the endothelium through a 
limbal incision in the feline model proved to be difficult. The anterior chamber of the cat is 
deeper than that of the human. However, the use of curved instruments can compensate in 
part for this difficulty. Feline’s Descemet’s layer is more adherent to the underlying stroma 
than that in human, which made stripping more difficult. Descemet’s adherence was such 
that pulling on it induced significant traction and distortion to the surrounding tissues with 
subsequent edema. In our cases, Descemet’s membrane was not peeled off in a single piece 
as it is the case in humans. We had to strip Descemet’s membrane piece by piece. The use 
of a blunt stripper made stripping of Descemet’s membrane easier, while sharp instruments 
such as Sinsky hook weren’t of much help. Furthermore, rapid fibrin formation inside the 
feline eye during surgery made manipulating the graft inside the eye difficult to perform. 
Mechanical removal of fibrin strands attached to the graft caused additional trauma. 
Intracameral injection of recombinant tissue plasminogen activator (rtPA) can partially help 
to resolve fibrin strands. Another limitation of DSAEK is the relative intolerance of the 
feline model to air in the anterior chamber.168 
Although significantly advantageous in humans over the traditional penetrating 
keratoplasty, DSAEK still has some limitations. The endothelial cell attrition in DSAEK 
may persist for years after surgery, with a cumulative endothelial cell loss of 67% of 
preoperative value and a continued risk of late endothelial failure 10 years after surgery.177 
Furthermore, endothelial cell loss is significantly higher using DSAEK compared to PKP 
technique 6 and 12 months postoperatively with comparable graft survival and comparable 
donor and recipient characteristics in humans. Price et al. attributed cell loss principally to 
greater surgical manipulation and trauma to the graft in the DSAEK procedure.20 Corneal 
endothelial immune rejection also occurs in about 27% of grafts, ultimately causing 
irreversible failure.22 In our DSAEK experiments in the feline model, postoperative 
observation showed moderate to severe intraocular inflammation with fibrin membrane 
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directed to the naked stroma of the donor. Suboptimal transparency of the tissue-engineered 
grafts was also observed. On the other hand, crystal clear transparency was achieved with 
the same tissue-engineered tissue with the PKP technique, with mild inflammatory reaction 
in some cases.29 Excessive surgical trauma and possible sensitivity towards naked donor 
stroma could be a possible explanation to this inflammatory reaction and decreased 
transparency in the feline model. In conclusion, our five DSAEK cases gave inconstant 
results in the feline model. 
5.5 Other Surgical Techniques 
Descemet membrane endothelial keratoplasty (DMEK)178 and  Descemet membrane 
automated endothelial keratoplasty (DMAEK)179 are interesting concepts that carry better 
and faster visual outcomes.180 The surgical procedure, however, is technically more 
challenging than DSAEK in humans, even in the hands of the most experienced surgeons. 
Handling a thin and fragile sheet of cells without stromal support that curls into a scroll 
inside the eye is an additional challenge compared to DSAEK. Quick per-operative fibrin 
formation inside feline eyes could make unfolding Descemet’s membrane even more 
difficult. Postoperative endothelial cells loss and requirement of air reinjection is even 
higher in DMAEK than in DSAEK.181 
For the reasons that were shown in this chapter, we chose to use the feline model 
and PKP technique for the in vivo assessment of TE-FECD corneas. 
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6.3 ABSTRACT   
Purpose: To evaluate the in vivo functionality of a corneal endothelium tissue-
engineered using corneal endothelial cells from human patients with Fuchs endothelial 
corneal dystrophy (FECD). 
Methods: Fifteen healthy cats underwent full-thickness corneal transplantation. All 
transplants were of xenogeneic human origin and all grafts but two were tissue-engineered. 
In seven animals the graft corneal endothelium was tissue-engineered using cultured 
corneal endothelial cells from humans with FECD (TE-FECD); Two control animals were 
grafted with an endothelium engineered using cultured endothelial cells from normal eye 
bank corneas (TE-normal); Two controls received a native full-thickness corneal transplant; 
and four other controls were grafted with the stromal carrier only (without endothelial 
cells). Outcome parameters included graft transparency (0 (opaque) to 4 (clear)), 
pachymetry, optical coherence tomography, endothelial cell morphometry, transmission 
electron microscopy (TEM) and immunostaining of function-related proteins.  
Results: Seven days after transplantation, 6 of 7 TE-FECD grafts, all TE-normal 
grafts and all normal native grafts were clear (transparency score > 3), while all carriers-
only grafts were opaque (score < 1). The mean pachymetry was 772 ± 102 µm for TE-
FECD, 524 ± 11 µm for TE-normal, 555 ± 48 for normal native and 1188 ± 223 µm for 
carriers only. TEM showed subendothelial loose fibrillar material deposition in all TE-
FECD grafts. The TE endothelium expressed Na+-K+/ATPase and Na+/HCO3-.  
Conclusion: Restoration of transparency and corneal thickness demonstrated that 
the TE-FECD grafts were functional in vivo. This novel FECD seven day living model 
suggests a potential role for tissue engineering leading to FECD cell rehabilitation.  
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6.4 INTRODUCTION  
Fuchs endothelial corneal dystrophy (FECD) is responsible for more than a quarter 
of the corneal transplantations performed in North America (28% of the 42,642 corneal 
grafts performed in the United-States in 2010).19 The pathophysiology of this inherited 
disease,91-93 however, is still poorly understood. Corneal edema is thought to result from 
decreased endothelial cell density, increased endothelial permeability and decreased 
endothelial pump function,7-12 and there is mounting evidence that oxidative stress, DNA 
damage and protein unfolding response leading to apoptosis may play a role in FECD 
pathogenesis.13-18 Very few experimental models are available to study FECD. A collagen 
VIII α2 Q455K knock-in mouse model has recently successfully been developed by Jun et 
al.182 for a rare type of early onset FECD. He et al.183 have cultured FECD corneal 
endothelial cells transfected with the human papilloma virus type 16 genes E6/E7 to expand 
their lifespan. Culture of FECD cells has proven to be difficult without transfecting 
oncogenes.  
Human corneal endothelial cells are arrested in the G1-phase of the cell cycle23 and 
do not proliferate in vivo. However, they can proliferate in vitro in response to growth-
promoting agents.24-26 Our laboratory has shown that normal corneal endothelial cells can 
be cultured and can retain function in vitro and in vivo.27-29 We demonstrated the first 
evidence of successful culture, without viral transduction, of corneal endothelial cells from 
patients with FECD.30 These cells were also successfully used to tissue engineer a corneal 
endothelium.184  
In this study, we evaluated the functionality of a corneal endothelium tissue-
engineered (TE) using corneal endothelial cells from human subjects with FECD, that were 
cultured on a devitalized human stromal carrier and transplanted in a living feline eye. This 
short-term in vivo experimental model for FECD was assessed and characterized. 
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6.5 MATERIALS AND METHODS 
All experiments were conducted in accordance with the Declaration of Helsinki and 
the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. The 
research protocol was approved by the Maisonneuve-Rosemont Hospital Animal Protection 
and Ethics for Clinical Research committees. 
6.5.1 Tissue Preparation 
Consenting patients with FECD undergoing DSAEK or penetrating keratoplasty 
(PKP) for symptomatic non-reversible corneal endothelial failure at the Maisonneuve-
Rosemont Hospital (Montreal) between October 2009 and September 2010 were enrolled in 
this study (four women, three men, aged from 58 to 74 years, mean ±SEM= 66 ± 6 years). 
At the time of DSAEK, the diseased Descemet's membrane (DM) and overlying 
endothelium were removed from the eye as described previously.30  No viscoelastic agent 
was used. The specimen was put in Optisol-GS (Bausch and Lomb, Rochester, NY) and 
sent on ice to the laboratory for cell isolation. For PKP, the full thickness corneal specimen 
was sent in Optisol-GS and DM was stripped upon arrival in the laboratory. 
FECD specimens were processed on the day following surgery. Endothelial cells 
were isolated as described by Zhu and Joyce26. In five cases, the cells were cryopreserved 
at P0 in 90% fetal bovine serum (Hyclone) /10% dimethylsulfoxide (DMSO; Sigma). The 
corneal endothelial cells were cultured as described previously184(Figure 49A) and seeded 
at P1 (n=1) or P2 (n=6) (initial seeding of  2.42 x 105 ± 0.34 x 105 cells) on a devitalized 
human stroma, on which they were grown for 1 to 2 weeks (10.9 ± 1 days, range from 8 to 
15 days). The tissue-engineered corneas were then preserved in transport medium29 for 1 to 
3 days (2.5 ±1 days, range from 1 to 3) prior to transplantation. 
Thirteen eye bank corneas from 13 donors were used to produce stromal carriers 
(mean age ±SEM: 62 ± 10 years (34 to 80 years)). Native cells were killed through three 
freeze (-20oC) /thaw cycles and the devitalized corneas were stored at -20oC until used 
(mean delay of 70 ± 77 days, from 8 to 531 days). The carriers to be transplanted without 
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endothelium were prepared in the exactly same manner, but without endothelial cell 
seeding. 
For comparison purposes, two corneas were also engineered using the endothelial 
cells of normal eye bank corneas. The two donors were aged 68 and 47 years. Central 
Descemet’s membrane was stripped using a circular biopsy punch (Acuderm, Dormer 
Laboratories, Toronto, ON, Canada) and fine forceps. Besides endothelial cell origin and 
isolation technique, all steps for tissue engineering of the normal and FECD corneas were 
identical. 
Ultrastructure studies of mate non-transplanted, tissue-engineered corneas 
confirmed the previously reported similarity between the TE-FECD and the TE-normal 
corneas in culture.184 The endothelial monolayer was attached to DM, with well preserved 
nuclei, mitochondria, and rough endoplasmic reticulum, all suggestive of healthy cellular 
activity (Figure 49B). DM was normal, without guttae or subendothelial deposition of loose 
fibrillar material. The stroma was acellular.  
For native controls, two normal eye bank corneas harvested within 12 hours after 
death were preserved in Optisol at 4°C and transplanted within 10 days after death. All eye 
bank tissues in this study were obtained from our local eye banks (Québec Eye Bank, 
Montréal, and Banque d’yeux du Centre universitaire d’ophtalmologie, Québec, QC, 
Canada) and were unsuitable for transplantation in humans. 
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Figure 49: Corneal endothelial engineered using FECD endothelial cells. (A) FECD 
endothelial cells in culture. (B) Transmission electron microscopy view of a mate non-
transplanted cornea engineered by seeding FECD endothelial cells on a devitalized stromal 
carrier. The endothelial cell is attached to DM and shows well preserved nucleus, numerous 
mitochondria and the presence of rough endoplasmic reticulum, all signs of healthy cellular 
activity. Note the absence of subendothelial deposition of loose fibrillar material. Scale 
bars: (A) 200 µm, (B) 1 µm. 
6.5.2 Tissue Assignment 
Fifteen animals underwent full-thickness corneal transplantation. All transplants 
were of xenogeneic human origin and all grafts but two were tissue-engineered. Seven 
animals were grafted with a corneal endothelium tissue-engineered using endothelial cells 
from patients with FECD, cultured on a devitalized stromal carrier (TE-FECD grafts). Two 
control animals were grafted with a corneal endothelium tissue-engineered using 
endothelial cells from normal eye bank corneas, cultured on a devitalized stromal carrier 
(TE-normal grafts). Two control animals received a normal native human cornea (normal 
native grafts). Four other controls were grafted with the stromal carrier only, without 
endothelial cells (carrier-only). One eye per animal was randomly assigned to surgery, and 
the contralateral unoperated eye was used as a control. 
6.5.3 Preoperative Management of the Animals 
Healthy animals aged 8 to 27 months (mean ± SEM: 13 ± 4 months) were obtained 
from a certified supplier. Standard ophthalmic examination of the animals included 
biomicroscopy (Haag-Streit, Bern, Switzerland), intraocular pressure measurement with a 
handheld veterinary tonometer (Tonovet, TV01; Tiolat Oy, Helsinki, Finland), and central 
corneal pachymetry (Ultrasound Pachymeter SP 3000; Tomey, Nagoya, Japan). 
Prophylactic famciclovir (Famvir, PMS, Montreal, QC) 125 mg/day per os was started on 
admission and continued over the entire study period. 
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6.5.4 Corneal Transplantation 
Surgery was performed under general anesthesia, using the premedication and 
systemic and topical medication described previously.141 The donor cornea was warmed at 
room temperature over 2 hours prior to transplantation. It was cut with a 9-mm Hanna 
punch (Moria, Antony, France). The recipient cornea was cut with an 8-mm trephine Weck 
(Solan Medtronics, Jacksonville, FL) and the anterior chamber was filled with viscoelastic 
(Healon, AMO, Santa Ana, CA). The donor tissue was gently rinsed with BSS and secured 
to the recipient bed with four cardinal sutures, followed by a 10–0 nylon single running 
suture (CU-1 10–0 nylon; Alcon Surgical, Fort Worth, TX). The viscoelastic was rinsed 
with BSS. A recombinant tissue plasminogen activator (Alteplase, Genentech, CA) (150 µg 
in 0.3 ml) was injected into the anterior chamber to stimulate resorption of the gelatinous 
stands of fibrin which tend to form in this species when the anterior chamber is entered. 
Suture knots were buried and the wound was checked for leaks using a fluorescein strip 
(Fluorescein sodium ophthalmic strips, Chauvin laboratories, Aubenas, France). 
6.5.5 Postoperative Medication 
At the end of surgery, all animals received subconjunctival injections of 
dexamethasone (1.2 mg in 0.3 ml), betamethasone (3mg in 0.5 ml), tobramycin (10 mg in 
0.25 ml) and cefazolin (55 mg in 0.25 ml), and an elizabethan collar was installed. Sodium 
chloride 5% (Muro 128, Bausch & Lomb, Rochester, NY), tobramycin 0.3% and 
dexamethasone 0.1% (Tobradex, Alcon) ointments were applied BID. Subconjunctival 
injections of dexamethasone (1.2 mg in 0.3 ml) or betamethasone (3mg in 0.5 ml) were 
repeated when an increase in intraocular inflammation was observed on two consecutive 
days. No systemic antibiotics were given at any time.  
6.5.6 Postoperative Follow-up 
Animals were examined daily by two independent observers. Graft transparency 
was quantified according to a subjective 0 to +4 scale: +4, clear graft; +3, slight opacity 
with iris/lens details easily visible; +2, mild opacity, iris/lens details still visible; +1, 
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moderate opacity with no iris/lens details; and 0, opaque cornea (iris not visible).29 Anterior 
chamber cells and flare were quantified according to a 0 to +4 scale (for cells: in a field size 
of 1 mm by 1 mm slit beam: 0: no cells; +1: occasional cells; +2: 8-15 cells; +3: too many 
to count; +4: very dense. The flare scale was quantified as: 0: empty; +1: very slight; +2: 
mild to moderate (iris/lens clear); +3: moderate (iris/lens hazy); +4: severe (fibrin, plastic 
aqueous).185 Intraocular pressure and central corneal thickness were measured on days 1, 2, 
3, 4, and 7. When measurements exceeded the measuring limit of the pachymeter (1400 
µm), this limit was arbitrary used as the corneal thickness value. 
6.5.7 Post-Mortem Assessment 
Animals were euthanized (pentobarbital sodium 3 ml/2.5-5 kg intravenously) on 
postoperative day 7 (±12 hours) to avoid the acute immune reaction known to occur 9 to 14 
days after transplantation.186 Operated and control eyes were enucleated and examined. 
Optical coherence tomography (OCT) was performed (OCT III or Visante 1000; Carl Zeiss 
Meditec, Dublin, CA) to assess graft thickness and to document the fine structures in the 
anterior chamber susceptible to be washed out during tissue processing for histology. 
6.5.8 Corneal Endothelial Cell Density 
Non-contact specular microscopy (Konan Medical INC., Nishinomiya, Hyogo, 
Japan) was performed on all eyes before surgery, while the postoperative cell counts were 
obtained from all eyes by vital staining of part of the excised corneas. The endothelium was 
stained with trypan blue (Sigma) and alizarin red S (Sigma)187 and photographed (SteREO 
Discovery V12, Carl Zeiss Canada, Toronto, ON, Canada). Endothelial morphometric 
analyses were made using the KSS-409SP software (version 2.10; Cellchek XL; Konan 
Medical Inc.). Three different fields were randomly selected for each corneal endothelium 
and a minimum of 100 cells per field were counted. The percentage of hexagonal cells was 
used as an index of pleomorphism and the coefficient of variation in cell area as a measure 
of polymegethism.67, 135  
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6.5.9 Histopathology 
A portion of each cornea was fixed in 10% neutral buffered formalin and paraffin 
embedded by standard techniques.  Sections were cut at 5 um and stained with hematoxylin 
& eosin. A small portion of each cornea was fixed in 2.5% glutaraldehyde for  transmission 
electron microscopy (Hitachi H-7500, Tokyo, Japan).27 For immunofluorescence staining, 
two samples of cornea were frozen in optimal cutting temperature solution (OCT) 
(Somagen; Edmonton, AB, Canada). Indirect immunofluorescence assay was performed on 
acetone fixed cryosections, as described by Proulx et al.29 Primary antibodies consisted in 
mouse monoclonal anti-Na+/K+-ATPase α1 (Millipore, Billerica, MA) and rabbit 
polyclonal anti– Na+/HCO3- (Chemicon, Temecula, CA). After three rinses in PBS, sections 
were incubated for 30 minutes at room temperature with secondary antibodies consisting in 
goat anti–mouse IgG or chicken anti–rabbit antibodies conjugated with Alexa 594 
(Invitrogen). Negligible background was observed for controls (primary antibodies 
omitted). Cell nuclei were counterstained with Hoechst reagent 33258.  
6.5.10 Statistical Analyses 
The Kruskal-Wallis exact test was used to test for differences in medians between 
groups. When the Kruskal-Wallis test was significant, pairwise comparisons were carried 
out with the exact Wilcoxon rank-sum test. The Pearson product-moment correlation 
coefficient was calculated when indicated. Mean values and standard error of the mean 
(SEM) are reported and a p value of less than 0.05 was considered to be statistically 
significant. All statistical tests were two-sided. The analyses were conducted using SAS 9.2 
(SAS Institute).  
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6.6 RESULTS  
6.6.1 Surgery 
Corneal transplantation was uncomplicated in all cases. In one of the carrier-only 
grafts, the running suture broke on the first day after surgery. It was re-sutured on the same 
day, but broke again on day 7. No reason could be identified for these repeated suture 
ruptures.  
6.6.2 Post-Transplantation Follow-up 
6.6.2.1 Graft Transparency  
TE-FECD grafts (Figure 50A-D) and TE-normal grafts (Figure 50E-H) were clear 
by biomicroscopy and OCT examination, although initially not as clear as the normal native 
grafts (Figure 50I-L). The carrier-only controls remained opaque until the last day (Figure 
50M-P). Evolution of the mean graft transparency score as a function of time after 
transplantation is illustrated in Figure 51A. After seven days, the mean (± SEM) score was 
3.14 ± 0.76 (range from 0.5 to 4) for the TE-FECD grafts, 3.25 ± 0.25 (3 to 3.5) for the TE-
normal controls, 3.5 ± 0 for the normal native controls and 0.56±0.09 (0.5 to 0.75) for the 
carrier-only controls. The clinically significant difference in graft transparency observed 
between groups tended to be statistically significant (Kruskal-Wallis: p=0.094). 
One of TE-FECD grafts behaved differently from the others. On the first day after 
surgery, a 360 degrees posterior wound gap was noticed between the graft and the recipient 
cornea, leading to recipient stromal edema at the wound. At day 4, the graft transparency 
score was 3 and the epithelium covered 60% of the graft surface. During the next following 
days, however, the epithelium was progressively lost and the exposed stroma rapidly 
became edematous, ulcerated and necrotic, reducing the transparency score to 0.5 at day 7. 
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Figure 50: Corneal grafts 7 days after transplantation. Representative slit lamp (columns 1-
3) and OCT (column 4) photos are shown. (A-D) Tissue-engineered graft with endothelial 
cells from a patient with Fuchs dystrophy. The graft is clear and thin allowing visualization 
of fine iris structure. Our transparency score in this case was 3.75/4 and the central corneal 
thickness was 659 µm. (E-H) Corneal transplant tissue-engineered from normal human 
endothelial cells. The graft is clear and thin (Transparency score = 3.5/4; Thickness = 513 
µm). A fine membrane of loose fibrin can be seen in the anterior chamber (H). (I-L) 
Normal native human corneal transplant. The graft is clear and thin (Transparency score = 
3.5/4; Thickness = 507 µm). A fibrin membrane can be seen in the anterior chamber (K-L). 
(M-P) Tissue-engineered corneal transplant consisting in a devitalized carrier without 
endothelial cells. The graft is opaque and edematous, with large sub-epithelial bullae 
(asterisk) and no detailed view of the iris (Transparency score = 0.5/4; Thickness = 1400 
µm). 
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6.6.2.2 Pachymetry 
The TE-normal grafts thinned continuously until their thickness reached that of the 
normal native controls (Figure 51B). The TE-FECD grafts also thinned progressively, 
although not as completely as the TE-normal grafts. The normal native controls remained 
thin and the carriers-only remained thick throughout the entire study period. On post-
operative day 7, the mean central thickness was 772 ± 102 µm (659 to 1023 µm) for the 
TE-FECD grafts, 524 ± 11 (513 to 535 µm) for TE-normal controls, 555 ± 48 µm (507 to 
603 µm) for normal native controls and 1188 ± 223 µm (742 to 1400 µm) for carriers only. 
The Kruskal-Wallis test confirmed an overall significant difference in corneal thickness 
median values among the four groups at day 7 (p=0.0048). Paired comparisons between 
TE-FECD and TE-normal grafts thicknesses tended to be statistically significant (p=0.07), 
as did paired comparisons between TE-FECD and native grafts thicknesses (p=0.07).   
6.6.2.3 Reepithelialization 
None of the tissue-engineered grafts were epithelialized at the time of 
transplantation. On day 7, six of the seven TE-FECD grafts were fully or almost fully 
reepithelialized (mean coverage of 97.3 ± 3 %) (Figure 51C). The case of corneal ulceration 
described above had practically no remaining epithelium at day 7. One of the two TE-
normal grafts was fully reepithelialized at day 7, while the epithelium of the other one 
remained fragile and edematous, covering only 25% of the graft surface at day 7. In one of 
the two normal native controls, the epithelium was removed during surgery but grew back 
rapidly to achieve full coverage at day 7, and in the other case, the epithelium remained 
intact throughout the study period. The carrier-only controls were reepithelialized at 97 ± 4 
% at day 7 in 3 cases out of 4. In the 4th case, epithelial coverage reached 50% at day 4 and 
decreased to 20% at day 7. 
6.6.2.4 Intraocular Pressure 
Before surgery, the mean intraocular pressure for both operated and non-operated 
eyes was 31 ± 9 mm Hg. No significant increase in intraocular pressure was observed after 
surgery (Figure 51D).  
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6.6.2.5 Intraocular Inflammation  
All eyes were quiet prior to surgery. On the first postoperative day, mild intraocular 
inflammation was present in the anterior chamber of all eyes. The number of inflammatory 
cells decreased progressively during the following 3 to 4 days, with a tendency to increase 
again by the end of the week in all four groups (Figure 51E). As the flare progressively 
diminished (Figure 51F), condensation of a fine fibrin formation reached its maximum at 
day 7. The fibrin deposition was characterized by spider-shaped filaments attaching to the 
edge of the graft and spreading over the graft posterior surface. The host cornea remained 
free of fibrin. Reactive inflammation is well known to be greater in the animal model than 
in human subjects.188 Neovascularization was not present in any transplanted tissue. 
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Figure 51: Clinical evolution of the operated eyes in the TE-FECD, TE-normal, normal 
native and carrier-only groups. (A) Transparency score. (B) Corneal thickness. (C) 
Epithelial coverage. (D) Intraocular pressure. (E) Anterior chamber cell score, (F) Anterior 
chamber flare score. All study cases are represented in these graphs, except for epithelial 
coverage, cells and flare at day 7 for the TE-FECD complicated case with stromal 
ulceration. Mean values are reported and error bars represent standard error of the mean. 
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6.6.3 Endothelial Cell Counts and Morphometry 
Tissue-engineered cells with an endothelial polygonal morphology in culture (as 
shown in Figure 49A) maintained their morphology on the stromal carrier in culture and in 
vivo. Alizarin red and trypan blue vital staining 7 days after transplantation showed full 
coverage of DM by polygonal cells in the TE and native grafts (Figure 52). Signs of 
endothelial stabilization and maturation of cell attachment were observed, with less space 
between cells than previously seen in culture. No endothelial cells were seen in any of the 
carrier-only controls (n=4).  
 
Figure 52: Alizarin red and trypan blue vital staining 7 days after transplantation. (A) TE-
FECD living endothelial cells covering Descemet’s Membrane (DM) surface. The cells 
have already developed a polygonal contour. Some inter-cellular spaces can be seen (dark 
spots) (Average± SD cell count was 942±445 cells/mm², average cell area was 1062 µm², 
CV was 42, 6-sided cells was 50%). (B) TE-normal endothelial cells seemed to be smaller 
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with fewer  inter-cellular spaces (Average± SD cell count was 1645±336 cells/mm², 
average cell area was 608 µm², CV was 55, 6-sided cells was 55%). (C) Normal native 
endothelial cells were small, polygonal with no inter-cellular space (Average± SD cell 
count was 2198±168 cells/mm², average cell area was 456 µm², CV was 37, 6-sided cells 
was 53%). (D) In the carrier-only controls, no endothelial cells were seen. Scale bars: 100 
µm. 
Seven days after transplantation, the average endothelial cell count was 966 ± 165 
cells/mm2 for TE-FECD grafts (n=5), 1929 ± 200 cells/mm2 for TE-normal controls (n=2) 
and 2371 ± 44 cells/mm2 for the normal native control (n=1) (Table 5). Cell morphometric 
analyses could not be obtained in two TE-FECD grafts, i.e. in one case because of the 
presence of a fibrin membrane masking the endothelial cells, and in the other case because 
cells could not be seen due to stromal opacification (case of corneal necrosis described 
above). The Kruskal-Wallis test confirmed an overall significant difference in postoperative 
endothelial median cell counts between the three groups (p=0.036). Interestingly, a strong 
negative correlation was observed between postoperative cell densities and central graft 
thickness at day 7 (r=-0.914; p=0.004), all three groups being considered together.  
As a corollary, TE-FECD endothelial cells were larger than TE-normal and normal 
native controls. The Kruskal-Wallis test confirmed a significant difference in median cell 
area between the three groups at day 7 (p=0.036). It was also interesting to notice that when 
the three groups were considered all together, cell area was positively correlated with graft 
thickness (r=0.785; p=0.037) and tented to be negatively correlated with graft transparency 
(r=-0.685; p=0.061) at day 7.  
Seven days after transplantation, the tissue-engineered endothelial cells reached a 
pattern closer to hexagonality than that observed in culture. Hexagonality is a sign of 
stability (contrary to endothelial mosaic disorganization, pleomorphism (differences in cell 
shape) and polymegethism (differences in cell sizes)). In the TE-FECD group, 41 ± 5 % of 
endothelial cells were hexagonal, compared with 41 ± 4 % for the TE-normal and 51 ± 5 % 
for the normal native grafts (Table 5). The cell area coefficient of variation was 53 ± 10 % 
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for TE-FECD grafts, 51 ± 7 % for TE-normal grafts and 38 ± 3 % for the normal native 
graft.  
 TE-FECD 
(n=5) 
TE-normal 
(n=2) 
Normal native 
(n=1) 
Carrier only
(n=4) 
Cell count (cells/mm2) 966 ± 165 1929 ± 200 2371 ± 44 0 
Cell area (μm2) 1110 ± 248 528 ± 56 422 ± 8 N/A 
SD of cell area 594 ± 157 268 ± 41 161 ± 13 N/A 
CV of cell area 53 ± 10 51 ± 7 38 ± 3 N/A 
6-sided cells (%) 41 ± 5 41 ± 4 51 ± 5 N/A 
Table 5: Endothelial cell counts and morphology. Average ± SEM are reported; N/A: not 
applicable.  
6.6.4 Histopathology 
6.6.4.1 Light Microscopy 
The corneal endothelial cells formed a monolayer in TE-FECD grafts in 6 cases 
(Figure 53A). No guttae were seen in any cases. The stroma was acellular, except in the 
periphery of the grafts where the keratocytes had started to migrate from the host stroma to 
the peripheral stroma of the graft. A small number of inflammatory cells were present in the 
stroma of three grafts. The restored epithelium consisted of 2 to 6 layers of cells that were 
well attached to graft Bowman’s membrane in 6 cases. In the case with corneal ulceration, 
the anterior stroma of the graft was massively infiltrated with inflammatory cells, with foci 
of anterior corneal necrosis. No microorganisms were identified. 
By light microscopy, TE-normal and TE-FECD grafts were very similar. In TE-
normal grafts, the endothelial monolayer was well attached to DM (Figure 53B), the host’s 
keratocytes had started to migrate into the graft periphery, a few inflammatory cells were 
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observed in the stroma of one of the grafts, and the regenerated epithelium consisted of 2 to 
4 layers of cells well attached to Bowman’s membrane. 
The native controls showed a regular endothelial monolayer well attached to the 
underlying DM (Figure 53C) and normal keratocytes present across the entire stroma. The 
epithelium consisted of 1 to 5 layers of cells well attached to Bowman’s membrane. 
Figure 53: Histological observations 7 days after transplantation. (A) TE-FECD graft (B) 
TE-normal graft showing endothelium consisting of a continuous monolayer endothelial 
cells firmly adherent to DM.  The stroma is acellular. (C) Normal endothelium of a native 
graft with native keratocytes in the stroma. Hematoxylin & eosin staining. Scale bars: 50 
µm. 
In the carrier-only controls, no endothelial cells were seen. The otherwise acellular 
graft stroma had been partially repopulated by the host keratocytes in the periphery. 
Numerous inflammatory cells were observed within the stroma of two grafts and the 
epithelium consisted of only 1 to 3 layers of cells attached to Bowman’s membrane. No 
neovascularization was seen in any of the 15 grafts. 
6.6.4.2 Transmission Electron Microscopy 
Overall, post-mortem TEM confirmed the progression of tissue-engineered 
endothelial monolayer stabilization, with a maturation of the cell-cell attachments, fewer 
and narrower intercellular gaps and more developed tight junctions than routinely seen in 
culture prior to transplantation.184 
In the TE-FECD grafts, the endothelium consisted of a 1.5 to 2.5 µm thick 
monolayer of cells (Figure 54A). Normal-appearing tight junctions were present (Figure 
54B). The endothelial cells generally were intact except that intercellular attachments were 
not always complete. Occasional apical V-shape separations of the cells (Figure 54C) or a 
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mid-height intercellular focal gaps (Figure 54D) were present laterally. The endothelial 
nuclei were unremarkable (Figure 54A, C, E). Numerous mitochondria were present 
(Figure 54F). Rough endoplasmic reticulum (RER) was generally prominent (Figure 54G). 
Vacuoles were present in some cells, as well as electron dense bodies consistent with 
lyzosomes (Figure 54H). A focal zone of dense intra-cytoplasmic filaments was seen in one 
case (Figure 54I). No pigment granules were present in any of the cases. Cytoplasmic 
processes were observed projecting either towards DM (Figure 54J), towards the anterior 
chamber (microvilli) (Figure 54E) or towards a neighboring cell (Figure 54D - arrows). The 
endothelium was attached to DM in all cases. Subendothelial deposition of loose fibrillar 
material was a consistent finding (Figure 54K). The carrier’s DM consisted in two normal 
anterior and posterior layers in all cases. No guttae were found in any of the cases. A few 
striated bodies (with a periodicity of 110 nm) were seen in the carrier’s DM of one TE-
FECD graft.  
No apparently viable keratocytes were observed in TEM specimens, which is not 
surprising as TEM samples were cut from the center of the grafts. Non-viable keratocyte 
material was observed across the entire stroma (Figure 54L), as remnants of the 
devitalization process. The space between stromal collagen fibers varied from 20 to 40 nm 
(Figure 55A).  
In the corneal ulceration case, the stroma was massively infiltrated with 
polymorphonuclear leukocytes and monocytes. Scattered degenerated endothelial cells 
were seen on the posterior surface of the graft.  
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Figure 54: Transmission electron microscopy. Ultrastructure of the TE-FECD grafts 7 days 
after transplantation. (A) Continuous monolayer of endothelial cells with intact nuclei. 
Normal DM. No guttata were present. (B) Complete cell-cell attachment showing tight 
junctions. (C) Incomplete apical cell-cell attachment. (D) Incomplete cell-cell attachment 
with intercellular residual gap. Arrows indicate basal and apical cytoplasmic projections 
attaching two adjacent cells. (E) Microvillus oriented toward the anterior chamber. (F) 
Normal appearing mitochondria. (G) Prominent RER with electron dense inclusion in 
Golgi apparatus. (H) Vacuoles and electron dense bodies consistent with lyzosomes. (I) 
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Intracytoplasmic filaments. (J) Cytoplasmic processes projecting towards DM. (K) 
Deposits of subendothelial fibrillar material. (L) Residual keratocyte debris in the 
devitalized stroma. Scale bars: (A) 2 µm, (B) 0.1 µm, (C-H, J) 0.5 µm, (I, K) 0.2 µm, (L) 1 
µm.    
In the TE-normal controls, the endothelium consisted of a 2.5 to 3.5 µm thick 
monolayer of cells (Figure 56A). The attachment between adjacent endothelial cells was 
generally intact (Figure 56B). Gaps between endothelial cells were occasionally seen, and 
when present, these gaps were less prominent than in the TE-FECD grafts. The 
endothelium was well attached to DM in all cases. Small amounts of subendothelial loose 
fibrillar material were observed in focal areas in one case. Small cytoplasmic processes 
were observed in one case projecting towards DM (Figure 56C). Nuclei were intact. 
Vacuoles were seen, as well as electron dense bodies consistent with lyzosomes. No 
pigment granules were seen. Mitochondria were unremarkable. RER was prominent (Figure 
56B). No intra-cellular filaments were seen. DM consisting of normal anterior and posterior 
layers was present in all the cases. No guttae were found. Residual non-viable keratocytes 
were observed in the stroma and the mean space between stromal collagen fibers was 25 
nm (Figure 55B). 
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Figure 55: Transmission electron microscopy. Stromal collagen fibers arrangement 7 days 
after transplantation. (A) TE-FECD graft showing a slightly irregular arrangement of the 
stromal collagen fibers. TE-normal graft (B) and normal native graft (C) showing a regular 
arrangement. (D) Carrier-only (without endothelial cells) grafts showing very irregular 
arrangement due to severe stromal edema. Scale bars: 100 nm. 
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In the normal native controls, the endothelium consisted of a 3.5 µm-thick 
monolayer of cells (Figure 56D). Adjacent endothelial cells were fully attached to each 
other and to underlying DM (Figure 56E). Cell nuclei, mitochondria and RER appeared 
normal (Figure 56F). Vacuoles and lyzosomes were observed. No cytoplasmic processes, 
pigment granules, intra-cellular filaments, or guttae were observed. DM consisted of 
normal anterior and posterior layers. Normal keratocytes were present throughout the 
stroma. The mean space between stromal collagen fibers was 15 nm (Figure 55C). 
 
Figure 56: Transmission electron microscopy. Ultrastructure of the TE-normal (A-C) and 
normal native (D-F) grafts 7 days after transplantation. (A) Continuous monolayer of 
endothelial cells with intact nuclei. (B-C) Complete cell-cell attachment with normal tight 
junctions. Prominent RER, normal appearing mitochondria, electron dense bodies 
consistent with lyzosomes, and cytoplasmic processes. Little subendothelial fibrillar 
material deposition. (D) Continuous monolayer of endothelial cells with normal nuclei. (E) 
Complete cell-cell attachment with mature tight junctions. Large vacuole-filled with cell 
debris. (F) Normal appearing mitochondria and RER. Absence of cytoplasmic processes 
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and subendothelial fibrillar material deposition. Scale bars: (A, D) 2 µm, (B-C, E-F) 0.5 
µm. 
TEM confirmed the absence of endothelial cells in the carrier-only controls. The 
DM was normal, without guttae. Residual non-viable keratocytes were observed in the 
stroma and the space between stromal collagen fibers was much larger, varying between 50 
and 100 nm (Figure 55D). 
6.6.4.3 Immunofluorescence 
Immunofluorescence detection of the sodium-potassium pump Na+/K+-ATPase α1 
and the Na+/HCO3- cotransporter revealed the presence of these proteins in all three types 
of endothelialized grafts. However, staining was less intense in TE grafts than in the normal 
native grafts (Figure 57).  
 
Figure 57: Immunofluorescence labeling of function-related proteins. Immunofluorescence 
detection of the sodium-potassium pump Na+/K+-ATPase α1 (A-D) and the Na+/HCO3- 
cotransporter (E-H) in a TE-FECD graft (A, E), a TE-normal graft  (B, F), a  normal native 
graft  (C, G), and in negative controls (incubated with secondary antibody only) (D, H). 
Cell nuclei were counterstained with Hoechst (blue). Scale bar: 20 µm. 
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6.7 DISCUSSION 
To the best of our knowledge, this study presents the first successful living model 
for FECD generated using untransformed human cells. We also demonstrated the first 
evidence that the sick endothelial cells of clinically decompensated FECD corneas, when 
cultured and seeded on a devitalized stromal carrier, can recover active pump function and 
restore and maintain corneal transparency for 7 days after transplantation in the living 
feline eye.  
6.7.1 Partial rehabilitation 
Overall, the tissue-engineered FECD endothelium seemed to perform better in the 
cat eye than in the patient’s eye. TE-FECD grafts progressively became thinner and clearer. 
Rare trypan blue staining of the nuclei, TEM observation of a well structured TE-FECD 
endothelial monolayer, with developed tight junction complexes, normal mitochondria, 
enlarged RER (sign of active protein production), lyzosomes and vacuoles, as well as the 
presence of endothelial pump sites observed by immunofluorescence, were all signs of 
healthy cellular activity.  
Explanations for this partial rehabilitation can only be hypothesized, since not 
specifically investigated in the present study. Proposed hypotheses include the beneficial 
effect of the culture conditions and/or the natural selection of the healthiest cells in culture. 
Removal of the diseased thickened DM may also have a played a role in the recovery of 
these endothelial cells. 
Partial rehabilitation of these end stage FECD endothelial cells and the 
demonstration of their in vivo functionality opens the door to an entirely new horizon.  
6.7.2 A clinical performance suggestive of early FECD 
However, despite this functional improvement, the TE-FECD corneas still did not 
perform normally in vivo and these corneas rapidly developed signs of mild to moderate 
Fuchs dystrophy. While considerably clearer and thinner than the negative controls without 
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endothelium, the TE-FECD grafts remained thicker than the TE-normal and the native 
controls. Endothelial cell density was also lower in TE-FECD grafts. 
6.7.3 TEM signs observed in native and tissue-engineered FECD corneas  
Several of the TEM signs typically reported in native FECD corneas were observed 
in this study. Subendothelial deposition of a layer of loose fibrillar material was 
systematically observed in TE-FECD grafts. Some subendothelial amorphous or fibrillary 
material was also seen in one of the TE-normal grafts, but in focal areas only and in smaller 
amounts than in the TE-FECD grafts. This excessive basement membrane like material 
production may reflect the known predisposition of FECD cells for excessive production of 
DM material. An abnormal thickening of DM is characteristic of native FECD, the normal 
anterior banded (fetal) and nonbanded layers being typically lined by two abnormal layers 
consisting in a posterior banded layer and a fibrillar layer.64, 66, 69, 71  
Incomplete closure of the cell-cell attachments, fewer and shorter tight junctions, 
residual gaps between adjacent cells, and an overall lower cell density were observed in the 
TE-FECD grafts. This may suggest that FECD endothelial cells were more susceptible to 
death, the remaining cells spreading to reach the next available cell in order to cover the 
area left by dying cells. This process would be very similar to that described in native 
FECD, where degenerating endothelial cells loosen their junctional complexes and 
disintegrate, leaving large intercellular gaps.66  
Intracytoplasmic filaments have been described by Iwamoto and DeVoe as a sign of 
transformation of the FECD endothelial cell into fibroblast-like cells,66 but they can also be 
occasionally seen in the normal endothelium.189 In our TEM specimens, endothelial 
intracytoplasmic filaments were only seen once in a TE-FECD graft.   
The pigment granules66, 68 seen in the patients’ specimens were not recovered in any 
of the engineered endothelia. Pigment granules have been reported to originate from the iris 
pigmented epithelium and to normally be phagocyted by the corneal endothelial cells.137 
The absence of pigment in the tissue-engineered endothelium is not surprising in the 
absence of an active source (such as the iris pigmented epithelium). The pigment granules 
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seen in the DSAEK specimens were probably either rinsed off or eliminated with the loss 
of the most dysfunctional cells. 
Striated bodies of various periodicity, size and distribution are typically seen in the 
DM abnormal posterior banded layer and guttae of native corneas with FECD.30, 40, 69-71 In 
this short-term study, no striated bodies were observed in the new DM-like material 
secreted by the engineered endothelium. No guttae formation were observed in this study, 
which was also compatible with the short duration of the follow-up. 
In summary, in the absence of a single pathognomonic sign, the diagnosis of FECD 
is usually based on a combination of signs typical of the disease. In the present study, all of 
the TE-FECD cells carried the genetic signature of the patient from whom they were 
harvested, and in all cases, these patients had a confirmed diagnosis of end-stage clinical 
FECD. Once transplanted back to a native living environment, this TE-FECD endothelium 
rapidly developed a combination of signs typical of FECD, including low endothelial cell 
counts, corneal edema, incomplete cell-cell attachments, and the accelerated and excessive 
production of DM-like subendothelial material. After only 7 days in the living eye, this 
short-term model, which carries the genetic background of FECD, gathered the key 
descriptors for early FECD. 
6.7.4 Characteristics of the proposed FECD model 
The FECD model we describe offers several significant advantages: (1) It is a living 
model; (2) it offers clinical and TEM quantifiable parameters for the characterization of 
TE-FECD endothelial function and structure. Clinical parameters include corneal 
transparency and corneal thickness (corneal transparency is still considered as the only real 
proof of endothelial functionality). TEM and histology parameters include a subendothelial 
layer of loose fibrillar material, which here appears to be the most specific sign of FECD, 
and less specific signs such as a decreased endothelial cell density, incomplete cell-cell 
attachment, and intracytoplasmic filaments. These parameters are very similar to those used 
to assess severity of the disease in native FECD; (3) it is polyvalent in that it is not limited 
to one specific mutation or cell line. In this paper, no selection was made in the choice of 
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FECD patients; (4) it allows for the in vivo selective investigation of FECD endothelial cell 
behavior in the absence of sick DM and guttae; (5) it allows for correlations between the 
FECD endothelial cells behavior in cell culture, in tissue culture, and in vivo, which can be 
very useful for the translational development of new therapies; and finally, (6) it was 
developed in the feline eye, which is functionally similar to the  human eye in several 
aspects. Feline corneal endothelial cells do not replicate in vivo,138 contrary to species such 
as the rat153 or rabbit,138, 140 and the feline endothelium repairs by cell spreading and 
migration,138 as in humans.156 Endothelial cell density 158, 160 and corneal thickness values 
are comparable to human values.163, 165 The large corneal diameter of the cat cornea (15.5-
18 mm)160, 167 permits full size grafts, using the same instrumentation and techniques as for 
human subjects. These large grafts also yield large amounts of tissue for postmortem 
analyses. And finally, short term human-to-cat corneal xenografts are well tolerated.146, 169 
Additional improvements to this model could include a longer follow-up. A 7 day 
follow-up period was chosen here to avoid xenograft rejection. A longer follow-up would 
require immunosuppression. 
6.7.5 Potential applications of this model 
The living experimental model for FECD we describe suggests many novel research 
opportunities with a goal of better understanding of FECD cell dysfunction, molecular 
pathophysiology and apoptosis. It offers the opportunity to test new therapeutic approaches 
at different stages of the disease.  
In addition to the development of a new living model for FECD, this study confirms 
the regenerative potential of FECD corneal endothelial cells in culture, making conceivable 
surgical therapeutic approaches in which the diseased corneal endothelial cells of Fuchs 
patients would be biopsied, cultured, treated, and used to engineer a healthy endothelium to 
be transplanted back to the patient (autograft). This would eliminate the risk of allograft 
rejection and constitute an exciting additional step toward a better management of this 
endothelial dystrophy. 
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In conclusion, we demonstrated herein the first evidence that the sick endothelial 
cells of clinically decompensated FECD corneas still retain proliferative capacity, allowing 
tissue engineering of a functional endothelium without transfection. Whether permitted by 
the favorable effect of the culture conditions or by the natural selection of the healthiest 
cells in culture, rehabilitation of end stage FECD endothelial cells and the demonstration of 
their in vivo functionality opens the door to an entirely new horizon of medical and surgical 
therapies.  
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7 Chapter VII:         
 General Discussion, Conclusions and Perspectives 
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7.1 General Discussion and Conclusions 
This thesis shows the first evidence of the feasibility of tissue engineering a corneal 
endothelium using endothelial cells from patients with Fuchs endothelial corneal dystrophy 
(FECD). These FECD tissue-engineered corneas were similar to tissue-engineered corneas 
using healthy endothelial cells in vitro at all studied levels (morphology, cell density, 
ultrastructure and protein expression). In fact, we could not differentiate the TE-FECD 
corneas from the TE-normal ones in aspect. The beneficial effect of the culture conditions, 
the natural selection of the healthiest cells in culture and/or the removal of the diseased 
thickened DM and guttae could explain the observed “normalization” of the TE-FECD 
corneas. 
  To the best of my knowledge, this is the first tissue model of FECD. Only few in 
vitro cellular models have been reported for FECD.183, 190 He et al.183 cultured FECD 
endothelial cells transduced with the human papilloma virus type 16 genes E6/E7 to expand 
their lifespan. Transduced FECD endothelial cells were similar to healthy in cell 
proliferation, morphology and two-dimensional gel protein electrophoretic patterns. The in 
vitro cellular model of He was recently used to study FECD pathogenesis. FECD 
endothelial cells were found to be more susceptible to oxidative DNA damage and 
oxidative-stress-induced apoptosis than normal.16 Kelliher et al.190 described a cellular 
model for FECD using Chinese hamster ovary cells transfected with collagen VIII α2 
mutations resulting in abnormal intracellular accumulation of collagen VIII. This ovary 
cellular model represents collagen VIII α2 mutations rather than FECD. Potential risks 
inherent to cell lines established by transfection, however, include latent potency for 
tumorigenicity, genetic instability and abnormal phenotypes. The transfer of genes into a 
cell modulates the cell’s protein expression, which can affect cell behavior. This may 
influence the effectiveness of studies on disease pathogenesis and may interfere with the 
treatment of these cells. The tissue model presented in this thesis is representative of any 
kind of FECD and is not restricted to any mutation or cell line. 
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We used a devitalized human stroma as a carrier for corneal tissue engineering. The 
advantages of this carrier are multiple. Native human corneas unsuitable for transplantation 
are frequently available in eye banks. Devitalization method is not complicated. 
Biocompatibility, physiological curvature, preservation of stromal collagen fibers 
arrangement and preservation of optical transparency property of the devitalized carrier 
have been previously demonstrated.29 The devitalized stromal carriers would be technically 
compatible with any corneal transplantation technique that is used for the treatment of 
endotheliopathies (PKP, DSAEK or DMEK). Besides, devitalized stromal carriers (free of 
living cells) seeded with autologous tissue-engineered endothelial cells are not expected to 
stimulate an immune reaction in the host.191 However, assessing mechanical compatibility 
is still needed. It’s important to demonstrate that this carrier is capable of providing the 
strength needed to help maintaining the shape of the cornea under the pressure of aqueous 
humor over time.  
Over the past 30 years, scientists made a remarkable progress of optimization and 
development of corneal endothelial cell isolation techniques and culture media.106 
However, not all endothelial specimens initiate culture and if they do, not all of them have 
typical endothelial morphology in culture.25, 26, 30 In the presented studies, only cultured 
endothelial cells with endothelial-like morphology (polygonal to slightly elongated shapes) 
were used for corneal tissue engineering. Developments in culture medium are still needed. 
Ideally, all biopsied endothelial specimens should initiate a culture regardless of the 
patient’s age, his chronic illness or his endothelial cell illness stage. Furthermore, all 
endothelial cells should have the typical endothelial cell morphology in culture. Recently, a 
serum free culture medium (SFM) was showed to protect endothelial cells from apoptosis 
and necrotic cell death.192 Rho-associated kinase (ROCK) inhibitor (Y-27632) was also 
showed to promote adhesion, increase proliferation and inhibit apoptosis of cultured 
endothelial cells.193, 194 
This thesis shows the first report of the DSAEK procedure in the feline model. 
Although the DSAEK procedure is currently the treatment of choice for endotheliopathies 
in humans,20, 195 it gave inconsistent clinical results in the feline model. The limitations of 
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DSAEK in my study were mostly related to technical difficulties and rapid fibrin formation 
in the feline model. Technical difficulties arise from the fact that cats have a large cornea, a 
deep anterior chamber, a DM that is attached firmly to the stroma and rapid fibrin 
formation during and after surgery. Using customized surgical tools designed for cats and 
mechanical scraping of the endothelium only leaving DM in place could solve part of the 
problem. Fibrin formation, however, is still a challenge. In our hands, fibrin strands 
attached to the graft once inserted inside the feline eye, acting like glue, making intraocular 
manoeuvres difficult to perform, which in turn caused additional trauma to the transplanted 
endothelium. rtPA injection helped partially in digesting the strands. After surgery, fibrin 
persisted to form strands targeting the naked stroma of the graft. Similar fibrin formation 
was also reported by Mohay120 and Bahn186 in the feline model after corneal 
transplantation. Honda et al.129 reported DSAEK in the rabbit model. The clinical outcome, 
however, was suboptimal (see section 5.4.4). Koizumi et al.142 recently reported a 
successful DSAEK in the monkey model. The clarity of the cornea was recovered by the 
second week after DSAEK. Minimal steroid treatment (ointment applied once daily for one 
month) was required. The monkey primitive model seems to have less inflammatory 
reaction than the feline model. 
This thesis presents the first successful in vivo model for FECD using tissue 
engineering. The TE-FECD corneas, that were tissue-engineered using endothelial cells 
from patients with clinical end-stage FECD, recovered an active pump function and 
restored and maintained corneal transparency for 7 days after transplantation in the living 
feline eye. This successful clinical performance suggests a potential role of tissue 
engineering for FECD cell rehabilitation. The TE-FECD corneas, however, showed a 
clinical performance suggestive of early FECD. While considerably clearer and thinner 
than the negative controls without endothelium, the tissue-engineered FECD grafts 
remained thicker than the tissue-engineered normal and the native normal controls. 
Endothelial cell density was also lower in the tissue-engineered FECD grafts. After only 
seven days of transplantation, there was a continuous deposition of loose fibrillar material 
under the endothelium in the tissue engineered FECD grafts which reflected the velocity of 
FECD endothelial cells in producing ECM, i.e. Descemet’s membrane. 
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To the best of my knowledge, only one in vivo experimental model has been 
reported for FECD.182 A collagen VIII α2 Q455K knock-in mouse model has recently been 
reported by Jun et al.182 This mutation caused a decrease in endothelial cell density, 
formation of guttae, dilated RER, unfolded protein response and apoptosis. Using this 
model, Matthaei et al.196 recently demonstrated that p21 is upregulated in FECD  
suggesting a premature senescence in FECD. This model, however, represents a rare type 
of early onset FECD, while our model is not limited to any mutation (see section 6.8.4). 
The postoperative follow-up period of our in vivo model was short. Following the 
animals for more than 7 days after surgery, however, is possible. It would necessitate 
immunosuppression, which was not possible with our set-up. Systemic immunosuppression 
requires special animal facilities, isolation, positive pressure rooms, Antibody Defined 
animals free of pathogens, and dedicated instrumentation. Shortness of follow-up could 
also be considered as an advantage. Within a period of only a few weeks, our model is 
combining the advantages of both in vitro and in vivo experimentation. Cell and tissue 
culture offers an initial period during which cell growth can be modulated within the 
controlled environment of the laboratory, followed by transplantation in the living eye, 
which still represents the only reliable test for corneal endothelial functionality. 
7.2 Perspectives 
To the best of my knowledge, this thesis shows the first successful in vitro and in 
vivo models for FECD using tissue engineering. This model opens the way to entirely new 
research perspectives for a better understanding of FECD cell dysfunction, pathophysiology 
and apoptosis. It offers the opportunity of testing new drugs at different stages of the 
disease. These could include, for instance, anti-oxidants against DNA oxidative damage;13, 
15, 16 Rho-associated kinase (ROCK) inhibitor (Y-27632) to promote adhesion, increase 
proliferation and inhibit apoptosis of cultured endothelial cells and to promote endothelial 
wound healing;142, 193, 194 and gene therapy that could induce endothelial cell proliferation 
and/or enhanced survival.197, 198  
In addition to the development of a new living model for FECD, this thesis confirms 
the regenerative potential of FECD endothelial cells in culture, making conceivable surgical 
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therapeutic approaches in which the diseased endothelial cells of Fuchs patients would be 
biopsied, cultured, treated, and used to engineer a healthy endothelium to be transplanted 
back in the patient (autograft). This would eliminate the risk of allograft rejection, reduce 
requirement for postoperative steroid therapy with its associated complications,191 and 
constitute an exciting additional step toward a better management of this common, painful 
and blinding disease. I believe that tissue engineering has the potential to be a useful tool in 
the future management of corneal endothelial diseases. 
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